Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Lung Cancer

Free Subscription Articles published in Clin Lung Cancer Retrieve available abstracts of 303 articles: HTML format

Single Articles

September 2025
1. DE MEO ML, Seitlinger J, Rayes RF, Walsh LC, et al
   KRAS ctDNA Detection in Patients With Resectable Lung Adenocarcinoma.
   Clin Lung Cancer. 2025;26:e447-e455.
   PubMed     Abstract available
   
   
   
2. BAZZI H, Thuo N, Sravanam S, Chen W, et al
   Evaluating Diagnostic and Treatment Timelines for ALK-Positive NSCLC Patients: Results From a Global Registry.
   Clin Lung Cancer. 2025;26:470-477.
   PubMed     Abstract available
   
   
   
3. BODOR JN, Dowell J, Treat J, Subramanian J, et al
   Phase II Trial of LP-300 in Combination With Carboplatin and Pemetrexed in Never Smoker Patients With Relapsed Advanced Primary Adenocarcinoma of the Lung After Treatment With Tyrosine Kinase Inhibitors.
   Clin Lung Cancer. 2025;26:511-514.
   PubMed     Abstract available
   
   
   
4. CANTOR DJ, Nimeiri H, Horn L, West M, et al
   Outcomes Following First-Line Immune Checkpoint Inhibitors With or Without Chemotherapy Stratified by KRAS Mutational Status-A Real-World Analysis in Patients With Advanced NSCLC.
   Clin Lung Cancer. 2025;26:503-510.
   PubMed     Abstract available
   
   
   
5. FAVE T, Nguyen J, Descourt R, Quere G, et al
   Real-life Experience of Rare Hepatoid Adenocarcinomas of the Lung: A Large Retrospective French Cohort.
   Clin Lung Cancer. 2025;26:e432-e440.
   PubMed     Abstract available
   
   
   
6. GOULD MK, de Bie E, Qi L, Creekmur B, et al
   Baseline Characteristics of Participants and Pulmonary Nodules in the Watch the Spot Trial: A Pragmatic Trial of Less versus More Intensive Strategies for Active Surveillance of Patients With Small Pulmonary Nodules.
   Clin Lung Cancer. 2025;26:e472-e482.
   PubMed     Abstract available
   
   
   
7. ZENG Z, Feng S, Gao T, Chen C, et al
   Efficacy and Safety of EGFR-TKI Combined With Early Brain Radiotherapy Versus TKI Alone in Patients With EGFR-Mutated NSCLC With Brain Metastases: A Systematic Review and Meta-Analysis.
   Clin Lung Cancer. 2025;26:e391-e398.
   PubMed     Abstract available
   
   
   
8. WATANABE T, Tanahashi M, Chiba M, Hashimoto K, et al
   Postoperative Pain Reduction and Clinical Value of Uniportal Video-Assisted Thoracic Surgery: A Secondary Analysis of the J-RATSIG 01 Study.
   Clin Lung Cancer. 2025;26:e413-e419.
   PubMed     Abstract available
   
   
   
9. MASUDA T, Katsumata S, Isaka M, Serizawa M, et al
   Impact of TP53 Co-Mutation on Clinicopathological Features, Prognosis, Recurrence Patterns, and the Efficacy of EGFR-TKI Treatment After Recurrence in Resected Early-Stage EGFR-Mutated Lung Adenocarcinoma.
   Clin Lung Cancer. 2025;26:e374-e381.
   PubMed     Abstract available
   
   
   
10. SOFIANIDI AA, Syrigos NK, Blyth KG, Charpidou A, et al
    Breaking Through: Immunotherapy Innovations in Pleural Mesothelioma.
    Clin Lung Cancer. 2025;26:458-469.
    PubMed     Abstract available
    
    
    August 2025
11. BRAMBILLA M, Barbetta F, Nardo G, Agnelli L, et al
    Refining High-Risk EGFR-Mutant Lung Cancer Patients: The Role of Adjusted Variant Allele Frequency in First-Line Osimertinib Therapy.
    Clin Lung Cancer. 2025 Aug 31:S1525-7304(25)00221.
    PubMed     Abstract available
    
    
    
12. DESAI A, McNeeley E, Alhushki S, Haught M, et al
    DISCERN: A Randomized Pilot Study Comparing Dual Versus Single Immune Checkpoint Blockade Plus Chemotherapy in PD-L1 Negative Advanced Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2025 Aug 26:S1525-7304(25)00220.
    PubMed     Abstract available
    
    
    
13. MORINAGA D, Furuta M, Morita S, Miyauchi E, et al
    A Phase 2 Study of Osimertinib in Combination With Platinum-Pemetrexed in Patients With Uncommon Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer (NEJ067/OPAL2).
    Clin Lung Cancer. 2025 Aug 26:S1525-7304(25)00219.
    PubMed     Abstract available
    
    
    
14. MUDD J, Zafar H, Mhango G, Slatore CG, et al
    Provider Bias in Decision Making About Treatment of Early-stage Lung Cancer With Stereotactic Body Radiation Therapy or Sub-lobar Resection.
    Clin Lung Cancer. 2025 Aug 23:S1525-7304(25)00217.
    PubMed    
    
    
    
15. BRONSTEIN A, Curcio H, Monnet I, Ricordel C, et al
    Rebiopsy Feasibility and Clinical Impact on Metastatic Non-Small-Cell Lung Cancer With EGFR/ALK/ROS Oncogenic Driver Progression After Optimal Targeted Therapy: A Multicenter Real-World Analysis.
    Clin Lung Cancer. 2025 Aug 21:S1525-7304(25)00198.
    PubMed     Abstract available
    
    
    
16. GUAY CA, Suhani A, Perreault L, Mai V, et al
    The Changing Landscape of Lung Cancer Resection Outcomes Over the Past two Decades.
    Clin Lung Cancer. 2025 Aug 13:S1525-7304(25)00189.
    PubMed     Abstract available
    
    
    
17. CAO W, Duan H, Shao C, Yan X, et al
    Achieving an Objective Response Following Two Cycles of Neoadjuvant Chemotherapy Plus Anti-PD-(L)1 Inhibitors Might Predict the Optimal Pathological Response in Resectable Stage II-III Nonsmall Cell Lung Cancer.
    Clin Lung Cancer. 2025 Aug 9:S1525-7304(25)00178.
    PubMed     Abstract available
    
    
    
18. MARAR R, Bai C, Hansen E, Zettler CM, et al
    Treatment Patterns and Outcomes of Non-Small Cell Lung Cancer with High PD-L1 Expression using Real World Evidence.
    Clin Lung Cancer. 2025 Aug 6:S1525-7304(25)00166.
    PubMed     Abstract available
    
    
    
19. REINMUTH N, Goldman JW, Chen Y, Hotta K, et al
    Durvalumab Plus Platinum-Etoposide in Extensive-Stage Small-Cell Lung Cancer: Outcomes in Age, Sex, and Platinum Subgroups From the Phase 3 CASPIAN Study.
    Clin Lung Cancer. 2025 Aug 6:S1525-7304(25)00164.
    PubMed     Abstract available
    
    
    
20. SUN F, Nagpal S, Singhal S, Neal JW, et al
    Brief Report: Safety of Pulse-Dose Osimertinib for Treatment of Leptomeningeal Disease or Refractory Brain Metastases in EGFR-Mutated Nonsmall Cell Lung Cancer.
    Clin Lung Cancer. 2025 Aug 6:S1525-7304(25)00165.
    PubMed     Abstract available
    
    
    
21. STOVER AM, Deal AM, Medley CJ, Weiner AA, et al
    Feasibility, Acceptability, and Utility of Remote Patient-Reported Outcomes Monitoring in Patients With Lung Cancer: A Moovcare(c) Study.
    Clin Lung Cancer. 2025 Aug 5:S1525-7304(25)00160.
    PubMed     Abstract available
    
    
    
22. VUONG SQ, Liu M, Tsarovsky NW, Wudtke JD, et al
    Outcomes of Patients With Interstitial Lung Disease and Early-Stage Non-Small Cell Lung Cancer Treated With Stereotactic Body Radiotherapy.
    Clin Lung Cancer. 2025 Aug 5:S1525-7304(25)00161.
    PubMed     Abstract available
    
    
    
23. VAKKALAGADDA CV, Bucheit L, Clemens K, Saha J, et al
    Impact of Incidental Germline BRCA1/2 and PALB2 Alterations on EGFR Monotherapy Real-World Outcomes for Patients With Advanced Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2025 Aug 5:S1525-7304(25)00151.
    PubMed     Abstract available
    
    
    July 2025
24. DEEK RA, Kim J, Kumar R, Medina B, et al
    Clinical and Genomic Features and Prognostic Biomarkers of Oligometastatic Nonsmall Cell Lung Cancer.
    Clin Lung Cancer. 2025 Jul 31:S1525-7304(25)00153.
    PubMed     Abstract available
    
    
    
25. YOO YJ, Song SY, Shin YS, Kim SS, et al
    What is the Optimal Dose and Fractionation Schedule for Inoperable Node-Negative Large (>/= 5 cm) Non-Small Cell Lung Cancer?
    Clin Lung Cancer. 2025 Jul 29:S1525-7304(25)00162.
    PubMed     Abstract available
    
    
    
26. DANESE MD, Shafrin J, Laurie M, Korytowsky B, et al
    Imaging Utilization and Treatment Patterns of Brain Metastases in Patients With Non-Small Cell Lung Cancer: A SEER-Medicare and SEER Database Analysis.
    Clin Lung Cancer. 2025 Jul 29:S1525-7304(25)00163.
    PubMed     Abstract available
    
    
    
27. TELLI TA, Tatli AM, Alan O, Keskin GY, et al
    Real-World Outcomes in BRAF-Mutant Non-small Cell Lung Cancer: A Multicenter Analysis From the Turkish Oncology Group.
    Clin Lung Cancer. 2025 Jul 22:S1525-7304(25)00159.
    PubMed     Abstract available
    
    
    
28. HATA T, Yamada T, Furuya N, Tanaka H, et al
    Analysis of Poor Prognostic Factors and Treatment Strategies in Platinum-Based Systemic Therapy After EGFR-TKI Failure in Patients With Advanced Nonsmall Cell Lung Cancer Harboring EGFR Mutations.
    Clin Lung Cancer. 2025 Jul 22:S1525-7304(25)00158.
    PubMed     Abstract available
    
    
    
29. KALKHORAN HA, Verschueren MV, Peters BJM, van de Garde EMW, et al
    Real World Effectiveness of Durvalumab in Stage III Unresectable Non-small Cell Lung Cancer: What is the Role of PD-L1 Expression?
    Clin Lung Cancer. 2025 Jul 17:S1525-7304(25)00154.
    PubMed     Abstract available
    
    
    
30. MORGILLO F, Del Signore E, Bria E, de Marinis F, et al
    The Italian Mauris Phase IIIb Trial of Atezolizumab Plus Carboplatin and Etoposide for Patients With Newly Diagnosed Extensive-Stage Small Cell Lung Cancer: 3-Year End-of-Study Results.
    Clin Lung Cancer. 2025 Jul 9:S1525-7304(25)00147.
    PubMed     Abstract available
    
    
    
31. BLOCH Z, Jensen S, Sorensen V, Langer SW, et al
    The Effect of Exercise on Quality of Life in Patients With Advanced Lung Cancer: A Secondary Analysis of a Randomized Controlled Trial.
    Clin Lung Cancer. 2025 Jul 9:S1525-7304(25)00149.
    PubMed     Abstract available
    
    
    
32. SHARP J, Young P, Zhao S, Wei L, et al
    Brief Report: Central Nervous System Metastases After Chemoradiation Followed by Durvalumab for Unresectable Locally Advanced Nonsmall Cell Lung Cancer.
    Clin Lung Cancer. 2025 Jul 5:S1525-7304(25)00146.
    PubMed    
    
    
    
33. LOCKE M, Aung WY, Esposito M, Seetharamu N, et al
    Lymphovascular Invasion is a Predictor of Postoperative Recurrence or Death in Stage I Non-small-cell Lung Cancer (NSCLC).
    Clin Lung Cancer. 2025 Jul 3:S1525-7304(25)00145.
    PubMed     Abstract available
    
    
    
34. WALIANY S, Hung YP, Rous FA, Luo F, et al
    Lung Carcinoid Tumors With Potentially Actionable Genomic Alterations and Responses to Targeted Therapies.
    Clin Lung Cancer. 2025;26:354-363.
    PubMed     Abstract available
    
    
    June 2025
35. WONG W, Li M
    Response to the Letter to the Editor on "CNS Outcomes of Osimertinib Plus Chemotherapy in Patients with EGFR Mutation-Positive Lung Cancer Beyond Osimertinib Progression".
    Clin Lung Cancer. 2025 Jun 26:S1525-7304(25)00143.
    PubMed    
    
    
    
36. ATLAGH L, Toublanc AC, Roch B, Marinello A, et al
    Clinical Outcomes of Compound EGFR Mutations in Non-Small Cell Lung Cancer: A National, Retrospective, Multicenter Study.
    Clin Lung Cancer. 2025 Jun 25:S1525-7304(25)00134.
    PubMed     Abstract available
    
    
    
37. ONDER AH
    Letter to the Editor: "CNS Outcomes of Osimertinib Plus Chemotherapy in Patients With EGFR Mutation-Positive Lung Cancer Beyond Osimertinib Progression".
    Clin Lung Cancer. 2025 Jun 20:S1525-7304(25)00142.
    PubMed    
    
    
    
38. HASHIM AG, Brondum RF, Nielsen MS, Laursen KL, et al
    Impact of Unsuccessful Steroid Tapering on Survival in Patients Treated for Radiation Pneumonitis Following Definitive Radiation for Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2025 Jun 19:S1525-7304(25)00133.
    PubMed     Abstract available
    
    
    
39. CAI OY, Fernandez JR, Aldrich MC, Richmond J, et al
    Assessing Factors Associated With Patient-Provider Discussions About Lung Cancer Screening Using Andersen's Behavioral Model of Health Services Utilization.
    Clin Lung Cancer. 2025 Jun 12:S1525-7304(25)00136.
    PubMed     Abstract available
    
    
    
40. SAKATA Y, Saito G, Sakata S, Yamaguchi T, et al
    Osimertinib as First-Line Treatment for Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in a Real-World Setting: Updated Overall Survival Data (OSI-FACT-OS).
    Clin Lung Cancer. 2025 Jun 10:S1525-7304(25)00129.
    PubMed     Abstract available
    
    
    
41. ROBINSON SD, Wong CD, Mazarakis NK, Lorimer C, et al
    A Review of Focal Therapies for Small Cell Lung Cancer Brain Metastases.
    Clin Lung Cancer. 2025 Jun 10:S1525-7304(25)00132.
    PubMed     Abstract available
    
    
    
42. MILLER M, Lautenschlaeger T, Birdas T, Hanna N, et al
    In the Era of Neoadjuvant Chemoimmunotherapy, is There a Role for Radiation Intensification Therapy in Patients With Stage III (N2) Non-Small Cell Lung Cancer (NSCLC) Who Undergo Surgery? Results of LUN17-321 in the Context of Current Clinical Treatme
    Clin Lung Cancer. 2025 Jun 10:S1525-7304(25)00131.
    PubMed     Abstract available
    
    
    
43. BAZHENOVA L, Hodgson JG, Camidge DR, Langer CJ, et al
    Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation Status.
    Clin Lung Cancer. 2025 Jun 6:S1525-7304(25)00128.
    PubMed     Abstract available
    
    
    
44. HENRIKSEN MB, Hilberg O, Juul C, Thomsen R, et al
    Maximizing Lung Cancer Screening in High-Risk Population Leveraging ML-Developed Risk-Prediction Algorithms: Danish Retrospective Validation of LungFlag.
    Clin Lung Cancer. 2025 Jun 4:S1525-7304(25)00130.
    PubMed     Abstract available
    
    
    
45. AHN JH, Choi SH, Park SH, Kim I, et al
    Longitudinal Analysis of Recurrence and Risk Factors of Early-Stage Resected Adenocarcinoma With Common EGFR Mutations: A Multicenter Retrospective Cohort Study in South Korea.
    Clin Lung Cancer. 2025;26:314-323.
    PubMed     Abstract available
    
    
    
46. CORRE R, Decroisette C, Auliac JB, Falchero L, et al
    First-Line Pembrolizumab Efficacy in Octogenarians With NSCLCs Expressing >/= 50% PD-L1 (ESCKEYP GFPC 05-2018).
    Clin Lung Cancer. 2025;26:331-337.
    PubMed     Abstract available
    
    
    
47. GUTTA R, Teslow E, Jaeger E, Stoppler MC, et al
    Racial Diversity and Co-Mutational Analysis of Biologically Relevant Alterations in EGFR Mutant Lung Cancers.
    Clin Lung Cancer. 2025;26:307-313.
    PubMed     Abstract available
    
    
    
48. LU C, Yan HH, Zhang CY, Chen SY, et al
    PEARL: A Multicenter Phase 2 Study of Lorlatinib in Patients with ALK-Rearranged NSCLC and Central Nervous System Disease.
    Clin Lung Cancer. 2025;26:263-266.
    PubMed     Abstract available
    
    
    May 2025
49. KRUITHOF PD, Brouns AJWM, Degens JHRJ, Hendriks LEL, et al
    Osimertinib Dose Optimization Guided by Therapeutic Drug Monitoring in Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Case series.
    Clin Lung Cancer. 2025 May 29:S1525-7304(25)00125.
    PubMed    
    
    
    
50. KOSTER KL, Yohasenan S, Pakmak AS, Mark M, et al
    Predictors of Multidisciplinary Tumor Board Adherence in Stage III Non-Small-Cell Lung Cancer Patients From a Large Multicenter Study.
    Clin Lung Cancer. 2025 May 29:S1525-7304(25)00124.
    PubMed     Abstract available
    
    
    
51. LIN JX, Zhou Q, Yan HH, Liu AW, et al
    A Patient-Centric, Open-Label, Multicenter, Phase II Study of Lorlatinib Monotherapy in the First-Line Treatment of Patients With locally Advanced or Metastatic ALK-Positive Non-Small Cell Lung Cancer (CTONG2203).
    Clin Lung Cancer. 2025 May 28:S1525-7304(25)00127.
    PubMed     Abstract available
    
    
    
52. PERUZZO N, Lenz G, Akhiwu T, Bilalaga M, et al
    Chemotherapy Plus Anti-PD-1 or Anti-PD-L1 in Advanced PD-L1-Negative Squamous Cell Lung Carcinoma: A Systematic Review and Meta-Analysis.
    Clin Lung Cancer. 2025 May 22:S1525-7304(25)00076.
    PubMed     Abstract available
    
    
    
53. RAKEDZON S, Mor E, Yechiel Y, Saiet Y, et al
    Correlation of PET-CT, Endobronchial Ultrasound Cytology and Surgical Biopsy in Patients with Non-Small Cell Lung Cancer Undergoing Curative Surgery.
    Clin Lung Cancer. 2025 May 18:S1525-7304(25)00103.
    PubMed     Abstract available
    
    
    
54. GWIN ME, Prasad T, Wahid U, Bhalla S, et al
    Mortality in a Diverse, Real-World Lung Cancer Screening Cohort.
    Clin Lung Cancer. 2025 May 13:S1525-7304(25)00102.
    PubMed     Abstract available
    
    
    
55. WATANABE Y, Koide Y, Shimizu H, Aoyama T, et al
    Combined Impact of Coronary Artery Calcification and Heart Radiation Dose on Overall Survival in Locally Advanced Non-Small Cell Lung Cancer: Who Benefits Most from Reducing Heart Radiation Dose?
    Clin Lung Cancer. 2025 May 12:S1525-7304(25)00100.
    PubMed     Abstract available
    
    
    
56. RIOS-GARCIA E, Guijosa A, Caballe-Perez E, Davila-Dupont D, et al
    Elucidating the Role of EGFR(L858R) in Brain Metastasis Among Patients With Advanced NSCLC Undergoing TKI Therapy.
    Clin Lung Cancer. 2025;26:e199-e206.
    PubMed     Abstract available
    
    
    
57. SOLIMAN MM, Gershon B, Ra DS, Escalon JG, et al
    Imaging Findings Related to Lung Tract Sealant Use in Percutaneous CT-guided Lung Biopsy.
    Clin Lung Cancer. 2025;26:236-243.
    PubMed     Abstract available
    
    
    
58. TAJE R, Ambrogi V, Tacconi F, Gallina FT, et al
    Kirsten Rat Sarcoma Virus Mutations Effect On Tumor Doubling Time And Prognosis Of Solid Dominant Stage I Lung Adenocarcinoma.
    Clin Lung Cancer. 2025;26:210-220.
    PubMed     Abstract available
    
    
    
59. TAKAMORI S, Endo M, Hamada A, Ohara S, et al
    Prognostic Analysis of Pathological Stage I Lung Adenocarcinoma Harboring Major EGFR Mutations.
    Clin Lung Cancer. 2025;26:e172-e180.
    PubMed     Abstract available
    
    
    
60. BRUNELLI A, Hoffman R, Wotton R, Baijal S, et al
    Surgical and Pathological Results Following Neoadjuvant Nivolumab and Platinum-Based Chemotherapy for Locally Advanced Resectable NSCLC: A Multicentre Real-World Series From England.
    Clin Lung Cancer. 2025;26:253-261.
    PubMed     Abstract available
    
    
    
61. PHAM D, Park JA, Wang H, Subramanian M, et al
    Computer Assisted Nodule Analysis and Risk Yield is Associated With Occult Lymph Node Status in Clinical Stage I-IIA Lung Adenocarcinoma Undergoing Resection.
    Clin Lung Cancer. 2025;26:e142-e149.
    PubMed     Abstract available
    
    
    April 2025
62. JOSEPHIDES E, Daddi N, Bertoglio P, Lugaresi M, et al
    A Propensity-Matched Comparison Between Minimally Invasive Surgery and Stereotactic Radiotherapy in the Treatment of Clinical Stage IA Non-Small-Cell Lung Cancer (NSCLC).
    Clin Lung Cancer. 2025 Apr 29:S1525-7304(25)00083.
    PubMed     Abstract available
    
    
    
63. PALECKI J, Tucker M, Bernstein A, Melby G, et al
    Multiple Sclerosis and Lung Cancer: A Single Cancer Center Experience in Philadelphia.
    Clin Lung Cancer. 2025 Apr 28:S1525-7304(25)00086.
    PubMed     Abstract available
    
    
    
64. OHAEGBULAM K, Anderson C, Thompson RF, Mitin T, et al
    Common Medical Comorbidities Influence Pneumonitis Risk After Chemoradiotherapy and Durvalumab Maintenance in Stage III Non-small Cell Lung Cancer.
    Clin Lung Cancer. 2025 Apr 24:S1525-7304(25)00082.
    PubMed     Abstract available
    
    
    
65. WEI L, Lao Y, Fu T, Xie Z, et al
    Distinct Role of TP53 Co-mutations in Different EGFR Subtypes Mediating the Response to EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2025 Apr 23:S1525-7304(25)00078.
    PubMed     Abstract available
    
    
    
66. TOPKAN E, Ozturk D, Selek U
    Comment on: Association of Sarcopenia with Toxicity and Survival in Patients With Lung Cancer, a Multi-Institutional Study With External Dataset Validation.
    Clin Lung Cancer. 2025 Apr 14:S1525-7304(25)00075.
    PubMed    
    
    
    
67. ODWUOR A, Lee P, Chang JY, Gandhi S, et al
    Outcomes and Toxicity following 3 or More Definitive Courses of Thoracic Radiation Therapy for Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2025 Apr 10:S1525-7304(25)00060.
    PubMed     Abstract available
    
    
    
68. MA R, Yang H, Ge Y, Ma T, et al
    Prognostic Implications of Lymph Node Status in Non-Small-Cell Lung Cancer Patients Before and After Neoadjuvant Chemoimmunotherapy: A Multicenter Retrospective Study.
    Clin Lung Cancer. 2025 Apr 8:S1525-7304(25)00062.
    PubMed     Abstract available
    
    
    
69. LEE YG, Seo D, Gil HI, Lee H, et al
    Assessment of Lung Cancer Risks Related to Family History in Never-Smokers: A Cohort Study.
    Clin Lung Cancer. 2025 Apr 8:S1525-7304(25)00061.
    PubMed     Abstract available
    
    
    
70. PINARD L, Ullur AR, Everest L, Zhan LJ, et al
    Real-World Creatinine-Based Estimates of Acute and Chronic Kidney Dysfunction in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer Receiving Tyrosine Kinase Inhibitors.
    Clin Lung Cancer. 2025 Apr 8:S1525-7304(25)00059.
    PubMed     Abstract available
    
    
    March 2025
71. OH MS, Garon EB, Lisberg AE, Cummings AL, et al
    Brief Report: The Genomic Landscape of Small Cell Lung Cancer in Never-Smoking Patients.
    Clin Lung Cancer. 2025 Mar 31:S1525-7304(25)00057.
    PubMed     Abstract available
    
    
    
72. KICKEN MP, Heine RT, Azarfane I, de Rouw N, et al
    The Toxicity Profile of Pemetrexed in Non-Small Cell Lung Cancer Patients With Moderate Renal Impairment: A Retrospective Cohort Study.
    Clin Lung Cancer. 2025 Mar 26:S1525-7304(25)00056.
    PubMed     Abstract available
    
    
    
73. BOLTE FJ, Dougherty SC, Danos AO, Lynch AC, et al
    Real-World Outcomes of Tarlatamab in Small Cell Lung Cancer, Including Patients With Untreated Brain Metastases.
    Clin Lung Cancer. 2025 Mar 26:S1525-7304(25)00052.
    PubMed     Abstract available
    
    
    
74. CHANG LC, Hu HW, Hsieh MS, Wu SG, et al
    Brief Report: The Effectiveness of Osimertinib in Advanced Nonsmall Cell Lung Cancer Harboring Various EGFR Exon 19 Mutation Variants.
    Clin Lung Cancer. 2025 Mar 21:S1525-7304(25)00054.
    PubMed    
    
    
    
75. SHARGALL Y, Vella ET, Del Giudice ME, Dennie C, et al
    Systematic Review for the Follow-up of Curatively Treated Patients With Lung Cancer.
    Clin Lung Cancer. 2025 Mar 19:S1525-7304(25)00049.
    PubMed     Abstract available
    
    
    
76. ELKEFI S, Phillips E, Groner LK, Matthews AK, et al
    Predictors of Up-To-Date Lung Cancer Screening Among Eligible People in the United States: A Nationally Representative Dataset.
    Clin Lung Cancer. 2025 Mar 17:S1525-7304(25)00051.
    PubMed     Abstract available
    
    
    
77. CASTANEDA-GONZALEZ JP, Parra-Medina R, Riess JW, Gandara DR, et al
    Genetic Ancestry and Lung Cancer in Latin American Patients: A Crucial Step for Understanding a Diverse Population.
    Clin Lung Cancer. 2025 Mar 13:S1525-7304(25)00050.
    PubMed     Abstract available
    
    
    
78. SARKARIA IS, Biro TG, Singhal S, Reddy RM, et al
    Intraoperative Molecular Imaging With Pafolacianine: Histologic Characteristics of Identified Nodules.
    Clin Lung Cancer. 2025;26:104-115.
    PubMed     Abstract available
    
    
    
79. EVIN C, Razakamanantsoa L, Gardavaud F, Papillon L, et al
    Clinical, Dosimetric and Radiomic Features Predictive of Lung Toxicity After (Chemo)Radiotherapy.
    Clin Lung Cancer. 2025;26:93-103.
    PubMed     Abstract available
    
    
    
80. STALKER M, Marmarelis M, Langer C, Cohen RB, et al
    Outcomes Following Treatment for Progression in Patients Treated With Durvalumab Consolidation in LA-NSCLC.
    Clin Lung Cancer. 2025;26:124-130.
    PubMed     Abstract available
    
    
    
81. ZHOU Q, Li J, Cang SD, Lin JX, et al
    FLAIR: A Phase II, Open Label, Randomized Study of Osimertinib Plus Bevacizumab Versus Osimertinib in Recurrent or Metastatic Treatment-Naive NSCLC Patients Harboring EGFR 21L858R Mutation.
    Clin Lung Cancer. 2025;26:152-157.
    PubMed     Abstract available
    
    
    
82. PAZ-ARES L, Gupta B, Baena J, Liu SV, et al
    Unmet Needs in Maintenance Therapy for Extensive Stage Small Cell Lung Cancer.
    Clin Lung Cancer. 2025 Mar 1:S1525-7304(25)00045.
    PubMed     Abstract available
    
    
    February 2025
83. MALIK PS, Pathak N, Sharma A, Birla M, et al
    Young Onset Lung Cancer in India: Insights Into Clinical, Demographic, and Genomic Profiles.
    Clin Lung Cancer. 2025 Feb 22:S1525-7304(25)00044.
    PubMed     Abstract available
    
    
    
84. WALLACE ND, Xie J, Alexander M, Ball D, et al
    Completion Rates for Patients Undergoing Concurrent Chemoradiotherapy for Stage III Nonsmall Cell Lung Cancer and its Importance in the Era of Consolidation Immunotherapy: A Cohort Study.
    Clin Lung Cancer. 2025 Feb 21:S1525-7304(25)00041.
    PubMed     Abstract available
    
    
    
85. ZHANG Y, Zhou SH, Yan YJ, Wu LL, et al
    Predicting Severe Radiation Pneumonitis in Patients With Locally-Advanced Non-Small-Cell Lung Cancer After Thoracic Radiotherapy: Development and Validation of a Nomogram Based on the Clinical, Hematological, and Dose-Volume Histogram Parameters.
    Clin Lung Cancer. 2025 Feb 21:S1525-7304(25)00042.
    PubMed     Abstract available
    
    
    
86. WILDER FG, McAllister M, Singh A, Xie Y, et al
    Lung Cancer in Patients Under 50: What is the Role of Social Determinants of Health?
    Clin Lung Cancer. 2025 Feb 20:S1525-7304(25)00039.
    PubMed     Abstract available
    
    
    
87. KULKARNI R, Zeine E, Potugari B, Gadgeel S, et al
    Small Cell Lung Cancer With de novo BRAF V600E Mutation and Durable Response to Targeted Therapy: A Case Report.
    Clin Lung Cancer. 2025 Feb 20:S1525-7304(25)00040.
    PubMed    
    
    
    
88. ROISMAN LC, Mann S, Basel A, Marei R, et al
    The PESGA Trial: A Prospective, Open-Label, Single-Arm, Phase II Study to Evaluate First Line Therapy for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Patients, Treated by Induction Carboplatin/Etoposide/Pembrolizumab Followed by Maintenance of Pe
    Clin Lung Cancer. 2025 Feb 13:S1525-7304(25)00027.
    PubMed     Abstract available
    
    
    
89. HE J, Liu Y, Wang X, Song R, et al
    The Impact of Radiation Dose to Immune Cells in Stage IV Non-Small Cell Lung Cancer in the Era of Immunotherapy.
    Clin Lung Cancer. 2025 Feb 13:S1525-7304(25)00036.
    PubMed     Abstract available
    
    
    
90. SHAH M, Noronha V, Patil V, Singh AK, et al
    Genomic Profiling of Driver Gene Alterations in Patients With Non-Small Cell Lung Cancer, Patterns of Treatment and Impact on Survival Outcomes: A Single Center Experience of More Than 1200 Patients.
    Clin Lung Cancer. 2025 Feb 11:S1525-7304(25)00026.
    PubMed     Abstract available
    
    
    
91. TRISOLINI R, Cetoretta V, Sotgiu G, Cancellieri A, et al
    Supraclavicular Lymph Node Metastases in Advanced Lung Cancer: Prevalence and Analysis of Demographic, Clinical and Molecular Characteristics.
    Clin Lung Cancer. 2025 Feb 8:S1525-7304(25)00033.
    PubMed     Abstract available
    
    
    
92. ALAPARTHI SS, Ho A, Rshaidat H, Whitehorn G, et al
    Outcomes of Segmentectomy With or Without Preoperative Biopsy in Non-Small Cell Lung Cancer (NSCLC).
    Clin Lung Cancer. 2025 Feb 8:S1525-7304(25)00034.
    PubMed     Abstract available
    
    
    
93. BARRICHELLO APC, Elkrief A, Ricciuti B, Ganta T, et al
    Tumor Immunophenotypic Correlates in Patients Aged 80 Years or Older With Non-Small Cell Lung Cancer and Outcomes to First-Line Pembrolizumab in PD-L1 High (>/=50%) Patients.
    Clin Lung Cancer. 2025 Feb 4:S1525-7304(25)00025.
    PubMed     Abstract available
    
    
    
94. OKSEN D, Boutmy E, Wang Y, Stroh C, et al
    Patients With Advanced Non-small Cell Lung Cancer Harboring MET Alterations: A Descriptive Cohort Study.
    Clin Lung Cancer. 2025 Feb 1:S1525-7304(25)00024.
    PubMed     Abstract available
    
    
    January 2025
95. ZHU Z, Wu J, Zhao L, Jiang N, et al
    Induction Immunochemotherapy Followed by Hypo-Fractionated Radiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2025 Jan 30:S1525-7304(25)00023.
    PubMed     Abstract available
    
    
    
96. SARAF A, He J, Shin KY, Weiss J, et al
    Association of Sarcopenia With Toxicity and Survival in Patients With Lung Cancer, a Multi-Institutional Study With External Dataset Validation.
    Clin Lung Cancer. 2025 Jan 28:S1525-7304(25)00021.
    PubMed     Abstract available
    
    
    
97. VERSCHUEREN MV, Hiensch DTA, Plomp PMJ, Kastelijn LA, et al
    Comparative Effectiveness of Nivolumab and Ipilimumab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in PD-L1 Negative Metastatic Non-Small Cell Lung Cancer Patients.
    Clin Lung Cancer. 2025 Jan 25:S1525-7304(25)00009.
    PubMed     Abstract available
    
    
    
98. PHILLIPS WJ, Jackson A, Kidane B, Lim G, et al
    Immunotherapy for Early-Stage Non-Small Cell Lung Cancer: A Practical Guide of Current Controversies.
    Clin Lung Cancer. 2025 Jan 15:S1525-7304(25)00006.
    PubMed     Abstract available
    
    
    
99. JOSEPHIDES EC, Smith D, Bille A, Patel A, et al
    A Retrospective Evaluation of PD-L1 Expression and Heterogeneity in Early-Stage Non-Small Cell Lung Cancer (REPLICA).
    Clin Lung Cancer. 2025 Jan 13:S1525-7304(25)00008.
    PubMed     Abstract available
    
    
    
100. WONG WKY, Mok KKS, Tsui GPC, Chen OH, et al
     CNS Outcomes of Osimertinib Plus Chemotherapy in Patients With EGFR Mutation Positive Lung Cancer Beyond Osimertinib Progression.
     Clin Lung Cancer. 2025 Jan 11:S1525-7304(25)00007.
     PubMed     Abstract available
     
     
     
101. LARA MS, Riess JW, Kaleka G, Borowsky A, et al
     POLE Mutation Associated With Microsatellite Instability and High Tumor Mutational Burden Confers Exquisite Sensitivity to Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer: A Case Report and Genomic Database Analysis.
     Clin Lung Cancer. 2025 Jan 8:S1525-7304(25)00005.
     PubMed    
     
     
     
102. HATA T, Yamada T, Goto Y, Amano A, et al
     Regimen Selection for Chemoimmunotherapy in Nonsquamous Non-Small Cell Lung Cancer with Low PD-L1 Expression: A Multicenter Retrospective Cohort Study.
     Clin Lung Cancer. 2025 Jan 4:S1525-7304(25)00001.
     PubMed     Abstract available
     
     
     
103. GEEVARGHESE R, Petre EN, Ziv E, Santos E, et al
     Transarterial Embolization for the Management of Emergent Hemoptysis in Patients With Primary and Metastatic Lung Tumors.
     Clin Lung Cancer. 2025;26:45-51.
     PubMed     Abstract available
     
     
     
104. HSIAO A, Woodward B, Ye P, Varga MG, et al
     Brief Report: Methylation-Based ctDNA Serial Monitoring Correlates With Immunotherapy Response in NSCLC.
     Clin Lung Cancer. 2025;26:72-77.
     PubMed     Abstract available
     
     
     
105. LEI B, Zhang H, Sun J, Wang L, et al
     The Potential of Basal F-18-FDG PET/CT in Evaluating Prognosis and Benefit From Adjuvant Chemotherapy After Tumor Resection of Stage IB(T2,
     Clin Lung Cancer. 2025;26:18-28.
     PubMed     Abstract available
     
     
     
106. SATO J, Yanagawa M, Nishigaki D, Hata A, et al
     Radiologists Versus AI-Based Software: Predicting Lymph Node Metastasis and Prognosis in Lung Adenocarcinoma From CT Under Various Image Display Conditions.
     Clin Lung Cancer. 2025;26:58-71.
     PubMed     Abstract available
     
     
     
107. ZHANG J, Wang Z, Wang Y, Yu X, et al
     Comparison of Long-Term Survival Between Robotic and Video-Assisted Lobectomy for Stage ? NSCLC With Radiologic Solid Tumors: A Propensity Score Matching Study.
     Clin Lung Cancer. 2025;26:e63-e72.
     PubMed     Abstract available
     
     
     
108. TAYLOR M, Martin GP, Abah U, Shackcloth M, et al
     Multicentre Validation of the RESECT-90 Prediction Model for 90-Day Mortality After Lung Resection.
     Clin Lung Cancer. 2025;26:e73-e80.
     PubMed     Abstract available
     
     
     December 2024
109. SAKANE T, Nakajima K, Iwata H, Hioki K, et al
     Comparison of Sublobar Resection and Proton Therapy for Early-Stage Non-small Cell Lung Cancer.
     Clin Lung Cancer. 2024 Dec 27:S1525-7304(24)00286.
     PubMed     Abstract available
     
     
     
110. LIU M, Guan W, Xie X, Li Z, et al
     Phase I Clinical Trial of Autologous Hematopoietic Stem Cell Transplantation-Supported Dose-Intensified Chemotherapy With Adebrelimab as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer.
     Clin Lung Cancer. 2024 Dec 27:S1525-7304(24)00287.
     PubMed     Abstract available
     
     
     
111. MARRONE MT, Reuss JE, Crawford A, Neelon B, et al
     Statin Use With Immune Checkpoint Inhibitors and Survival in Nonsmall Cell Lung Cancer.
     Clin Lung Cancer. 2024 Dec 25:S1525-7304(24)00271.
     PubMed     Abstract available
     
     
     
112. WEI CX, Althouse SK, Mamdani H, Hanna NH, et al
     Association of Immune-Related Adverse Events With Efficacy in Consolidation Nivolumab Plus Ipilimumab or Nivolumab Alone After Chemoradiation in Patients With Unresectable Stage III Nonsmall Cell Lung Cancer: An Exploratory Analysis From the Big 10 Ca
     Clin Lung Cancer. 2024 Dec 21:S1525-7304(24)00270.
     PubMed     Abstract available
     
     
     
113. KAWAHARA M, Matsuura Y, Nakamura S, Kinoshita F, et al
     Adjuvant Chemotherapy Decisions in the Treatment of Lung Cancer Considering Nonrelapse Mortality: A Multicenter Study.
     Clin Lung Cancer. 2024 Dec 21:S1525-7304(24)00272.
     PubMed     Abstract available
     
     
     
114. GOLDMAN JW, Bueno AM, Dooms C, Jhaveri K, et al
     Neratinib Efficacy in Patients With EGFR Exon 18-Mutant Non-Small-Cell Lung Cancer: Findings From the SUMMIT Basket Trial.
     Clin Lung Cancer. 2024 Dec 11:S1525-7304(24)00266.
     PubMed     Abstract available
     
     
     
115. TAKEDA M, Ota M, Iwama E, Sugawara S, et al
     A Phase II, Open Label, Single-Arm Study on the Efficacy of Cabozantinib in Patients With Advanced/Metastatic Nonsmall Cell Lung Cancer Harboring MET Exon 14 Alterations who Developed Acquired Resistance to Tepotinib or Capmatinib (CAPTURE Trial).
     Clin Lung Cancer. 2024 Dec 9:S1525-7304(24)00267.
     PubMed     Abstract available
     
     
     
116. ENRICO D, Gomez JE, Aguirre D, Tissera NS, et al
     Efficacy of First-Line Nivolumab Plus Ipilimumab in Unresectable Pleural Mesothelioma: A Multicenter Real-World Study (ImmunoMeso LATAM).
     Clin Lung Cancer. 2024;25:723-731.
     PubMed     Abstract available
     
     
     
117. HUET C, Basse C, Knetki-Wroblewska M, Chilczuk P, et al
     Outcomes Analysis of Patients Receiving Local Ablative Therapy for Oligoprogressive Metastatic NSCLC Under First-Line Immunotherapy.
     Clin Lung Cancer. 2024;25:e402-e410.
     PubMed     Abstract available
     
     
     
118. LEONETTI A, Cervati V, Minari R, Scarlattei M, et al
     Liquid Biopsy and 18F-FDG PET/CT Derived Parameters as Predictive Factors of Osimertinib Treatment in Advanced EGFR-Mutated NSCLC.
     Clin Lung Cancer. 2024;25:e436-e445.
     PubMed     Abstract available
     
     
     
119. DAMHUIS R, Bahce I, Senan S
     Association Between PD-L1 Score and the Outcomes of Consolidation Durvalumab in a Large Nationwide Series of Patients With Stage III NSCLC Treated With Chemoradiotherapy.
     Clin Lung Cancer. 2024;25:683-689.
     PubMed     Abstract available
     
     
     
120. SMITH MR, Wang Y, Dixon CB, D'Agostino R, et al
     Mutations Associated With High-Grade irAEs in NSCLC Patients Receiving Immunotherapies.
     Clin Lung Cancer. 2024;25:e379-e388.
     PubMed     Abstract available
     
     
     
121. LARA MS, Riess JW, Goldman JW, Jiang F, et al
     Current Trial Report: A Multicenter Phase I/Ib study of Capmatinib Plus Trametinib in Patients With Metastatic Nonsmall Cell Lung Center Harboring MET Exon 14 Skipping Mutations and Other MET-Alterations.
     Clin Lung Cancer. 2024;25:732-737.
     PubMed     Abstract available
     
     
     November 2024
122. WANG M, Wang X, Yang R, Geng M, et al
     Conversion Surgery for Initially Unresectable Stage ? Nonsmall Cell Lung Cancer After Induction Treatment of Immunochemotherapy: A Multicenter Study.
     Clin Lung Cancer. 2024 Nov 28:S1525-7304(24)00249.
     PubMed     Abstract available
     
     
     
123. GHARZAI LA, Bell S, Gupta DM, Carlos RC, et al
     Impact of Lung Biomarker Testing on Out-Of-Pocket Costs for Metastatic Non-Small-Cell Lung Cancer.
     Clin Lung Cancer. 2024 Nov 23:S1525-7304(24)00255.
     PubMed     Abstract available
     
     
     
124. WHITEHORN GL, Rshaidat H, Madeka I, Martin J, et al
     Lobectomy Is Not Associated With Improved Survival as Compared to Segmentectomy in Early-Stage Lung Cancer Patients With Visceral Pleural Invasion.
     Clin Lung Cancer. 2024 Nov 18:S1525-7304(24)00253.
     PubMed     Abstract available
     
     
     
125. STUMM TW, Mina S, Okusanya O, Cowan S, et al
     Metrics for Perioperative Exercise in Patients Undergoing Lung Cancer Resection: A Systematic Review.
     Clin Lung Cancer. 2024 Nov 16:S1525-7304(24)00252.
     PubMed     Abstract available
     
     
     
126. LIU J, Cao B, Shi Z, Song M, et al
     Correlation Between the Extent of N1 Lymph Node Station Examination and Prognosis in Stage I Non-small Cell Lung Cancer Patients: One Station is Insufficient.
     Clin Lung Cancer. 2024 Nov 16:S1525-7304(24)00250.
     PubMed     Abstract available
     
     
     
127. PARK JA, Pham D, Nilsson K, Ramsey L, et al
     Enhanced Recovery With Aggressive Ambulation Decreases Length of Stay in Lung Cancer Surgery.
     Clin Lung Cancer. 2024 Nov 16:S1525-7304(24)00251.
     PubMed     Abstract available
     
     
     
128. LIBBY DM, Libby LJ, Ma X, Chua J, et al
     Association of Oncogene Driver Mutations with Recurrence and Survival in Stage I Nonsmall Cell Lung Cancer.
     Clin Lung Cancer. 2024 Nov 14:S1525-7304(24)00233.
     PubMed     Abstract available
     
     
     
129. GARCIA C, Abrahami D, Polli A, Chu H, et al
     Comparative Efficacy and Safety of Lorlatinib Versus Alectinib and Lorlatinib Versus Brigatinib for ALK-Positive Advanced/Metastatic NSCLC: Matching-Adjusted Indirect Comparisons.
     Clin Lung Cancer. 2024;25:634-642.
     PubMed     Abstract available
     
     
     
130. MURATA S, Horinouchi H, Morishita M, Kaku S, et al
     Impact of Durvalumab on the Duration and Complexity of Corticosteroid Therapy for Pneumonitis After Chemoradiotherapy.
     Clin Lung Cancer. 2024;25:e369-e378.
     PubMed     Abstract available
     
     
     
131. CHOU KN, Park DJ, Hori YS, Persad AR, et al
     Primary Stereotactic Body Radiotherapy for Spinal Bone Metastases From Lung Adenocarcinoma.
     Clin Lung Cancer. 2024;25:e337-e347.
     PubMed     Abstract available
     
     
     
132. DEMIR T, Araz M, Moloney C, Hendem E, et al
     Efficacy of Systemic Treatments in Patients With Metastatic Lung Invasive Mucinous Adenocarcinoma.
     Clin Lung Cancer. 2024;25:e316-e322.
     PubMed     Abstract available
     
     
     
133. SCHMID S, Zhan L, Garcia M, Dietrich K, et al
     Immediate Versus Deferred Systemic Therapy in Patients With Mesothelioma.
     Clin Lung Cancer. 2024;25:e277-e285.
     PubMed     Abstract available
     
     
     October 2024
134. KUMAR MS, Deshmukh S, Bhanushali C, Boumber Y, et al
     Biomarker Landscape of Antibody Drug Conjugates (ADCs) and Bispecific Antibodies in Clinical Trials for Lung Cancer.
     Clin Lung Cancer. 2024 Oct 31:S1525-7304(24)00222.
     PubMed    
     
     
     
135. FORTMAN D, Wang H, VanderWeele R, Evans T, et al
     Brief Report: Phase II Clinical Trial of Atezolizumab in Advanced Nonsmall Cell Lung Cancer Patients Previously Treated With PD-1-Directed Therapy.
     Clin Lung Cancer. 2024 Oct 30:S1525-7304(24)00231.
     PubMed    
     
     
     
136. MATHIOT L, Raimbourg J
     Comment on ;;Prognostic Impact of TP53 Mutations in Metastatic Nonsquamous Non-small-cell Lung Cancer''.
     Clin Lung Cancer. 2024 Oct 28:S1525-7304(24)00224.
     PubMed    
     
     
     
137. JIANG L, Jiang S, Miao W, Shen Y, et al
     Clinical Characteristics and Management of Checkpoint Inhibitor Pneumonitis in Non-Small-Cell Lung Cancer Patients After Neoadjuvant Immunotherapy.
     Clin Lung Cancer. 2024 Oct 28:S1525-7304(24)00229.
     PubMed     Abstract available
     
     
     
138. CHAN SWS, Zeng J, Young J, Barghout SH, et al
     A Poor Prognostic ALK Phenotype: A Review of Molecular Markers of Poor Prognosis in ALK Rearranged Nonsmall Cell Lung Cancer.
     Clin Lung Cancer. 2024 Oct 28:S1525-7304(24)00223.
     PubMed     Abstract available
     
     
     
139. QASIM R, Riaz Z
     Comment on "Prognostic Impact of TP53 Mutations in Metastatic Nonsquamous Non-Small-Cell Lung Cancer".
     Clin Lung Cancer. 2024 Oct 25:S1525-7304(24)00225.
     PubMed    
     
     
     
140. CHOW JCH, Chik JYK, Cheung KM, Lee LTY, et al
     Phrenic Nerve Palsy after Stereotactic Body Radiotherapy for Central Lung Cancer: A Case Report.
     Clin Lung Cancer. 2024 Oct 18:S1525-7304(24)00210.
     PubMed    
     
     
     
141. LEI F, Sekkath-Veedu J, Huang B, Chen Q, et al
     Inclusion of Surgery in Multimodality Treatment is Predictive of Better Survival in Stage IIIA Non-small Cell Lung Cancer: An Inverse Probability Treatment-Weighting Analysis.
     Clin Lung Cancer. 2024 Oct 18:S1525-7304(24)00221.
     PubMed     Abstract available
     
     
     
142. SEITLINGER J, Patel D, Meng A, Bulgarelli-Maqueda L, et al
     Perioperative Outcomes of Neoadjuvant Therapy in Resectable Lung Cancer Patients With Endobronchial Disease in the Era of Personalized Medicine.
     Clin Lung Cancer. 2024 Oct 16:S1525-7304(24)00208.
     PubMed     Abstract available
     
     
     
143. WONG LY, Kapula N, Kang A, Phadke AJ, et al
     The Role of Primary Care Providers in Lung Cancer Screening: A Cross-Sectional Survey.
     Clin Lung Cancer. 2024 Oct 9:S1525-7304(24)00206.
     PubMed     Abstract available
     
     
     
144. JO Y, Puri S, Haaland B, Coletta AM, et al
     Augmenting Prognostication: Utilizing Activity Trackers to Enhance Survival Prediction in Metastatic Non-Small Cell Lung Cancer.
     Clin Lung Cancer. 2024 Oct 9:S1525-7304(24)00205.
     PubMed     Abstract available
     
     
     
145. WHEELER M, Karanth S, Divaker J, Yoon HS, et al
     Participation in Non-small Cell Lung Cancer Clinical Trials in the United States by Race/Ethnicity.
     Clin Lung Cancer. 2024 Oct 4:S1525-7304(24)00204.
     PubMed     Abstract available
     
     
     
146. YOSHIOKA H, Ishida T, Atagi S, Tamiya A, et al
     Randomized Phase II Trial of Amrubicin Plus Irinotecan Versus Cisplatin Plus Irinotecan in Chemo-naive Patients With Extensive-Disease Small-Cell Lung Cancer: Results of the Japan Multinational Trial Organization (JMTO) LC 08-01.
     Clin Lung Cancer. 2024 Oct 1:S1525-7304(24)00197.
     PubMed     Abstract available
     
     
     
147. PRICE SN, Willis AR, Hensley A, Hyson J, et al
     Implementation and Retrospective Examination of a Lung Cancer Survivorship Clinic in a Comprehensive Cancer Center.
     Clin Lung Cancer. 2024 Oct 1:S1525-7304(24)00203.
     PubMed     Abstract available
     
     
     September 2024
148. RSHAIDAT H, Mack SJ, Koeneman SH, Martin J, et al
     The Role of Medicaid Expansion on the Receipt of Adjuvant Chemotherapy in Patients With Lung Cancer.
     Clin Lung Cancer. 2024 Sep 24:S1525-7304(24)00202.
     PubMed     Abstract available
     
     
     
149. ROBINSON ND, Canavan ME, Zhan PL, Udelsman BV, et al
     Treatment Patterns and Clinical Outcomes in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer After Progression on Osimertinib.
     Clin Lung Cancer. 2024 Sep 23:S1525-7304(24)00201.
     PubMed     Abstract available
     
     
     
150. SPICER J, Blais N, Owen S, Robinson AG, et al
     A Phase II Study of Neoadjuvant Opnurasib KRAS G12C Inhibitor in Patients With Surgically Resectable Non-Small Cell Lung Cancer (CCTG IND.242A): A Substudy of the IND.242 Platform Master Protocol.
     Clin Lung Cancer. 2024 Sep 20:S1525-7304(24)00198.
     PubMed     Abstract available
     
     
     
151. WATSON AS, Krause HB, Elliott A, Farrell A, et al
     Use of Oncogene Overlap by Tissue-Based Next-Generation Sequencing to Explore the Mutational Landscape and Survival Impact of HER2, KRAS and MET Copy-Number Gain in Nonsmall Cell Lung Cancer.
     Clin Lung Cancer. 2024 Sep 12:S1525-7304(24)00196.
     PubMed     Abstract available
     
     
     
152. GRABER-NAIDICH A, Choi E, Wu JT, Ellis-Caleo TJ, et al
     Smoking and the Risk of Second Primary Lung Cancer Among Breast Cancer Survivors from the Population-Based UK Biobank Study.
     Clin Lung Cancer. 2024 Sep 6:S1525-7304(24)00195.
     PubMed     Abstract available
     
     
     
153. MEYER ML, Gros L, Decosterd N, Tagliamento M, et al
     Brief Report: Targeted Therapies and Pancreatitis in Patients With Advanced Nonsmall Cell Lung Cancer.
     Clin Lung Cancer. 2024 Sep 3:S1525-7304(24)00194.
     PubMed    
     
     
     
154. RECK M, Nadal E, Girard N, Filippi AR, et al
     MDT-BRIDGE: Neoadjuvant Durvalumab Plus Chemotherapy Followed by Either Surgery and Adjuvant Durvalumab or Chemoradiotherapy and Consolidation Durvalumab in Resectable or Borderline-resectable Stage IIB-IIIB NSCLC.
     Clin Lung Cancer. 2024;25:587-593.
     PubMed     Abstract available
     
     
     
155. HISHIDA T, Okami J, Asamura H, Miyaoka E, et al
     Clinicopathological Features and Survival Outcomes of Resected Lung Adenosquamous Carcinoma: Results From a Nationwide Japanese Registry Data.
     Clin Lung Cancer. 2024;25:519-528.
     PubMed     Abstract available
     
     
     
156. VELCHETI V, Rai P, Kao YH, Chirovsky D, et al
     5-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression >/= 50% Advanced NSCLC.
     Clin Lung Cancer. 2024;25:502-508.
     PubMed     Abstract available
     
     
     
157. RSHAIDAT H, Whitehorn GL, Collins M, Mack SJ, et al
     Factors Associated With Margin Positivity After Lung Resection Surgery.
     Clin Lung Cancer. 2024;25:560-566.
     PubMed     Abstract available
     
     
     
158. CONCANNON KF, Glisson BS, Doebele RC, Huang C, et al
     A Phase I Open-Label Study of Cediranib Plus Etoposide and Cisplatin as First-Line Therapy for Patients With Extensive-Stage Small-Cell Lung Cancer or Metastatic Neuroendocrine Non-Small-Cell Lung Cancer.
     Clin Lung Cancer. 2024 Sep 1:S1525-7304(24)00193.
     PubMed     Abstract available
     
     
     August 2024
159. NARRA K, Ghabach B, Athipatla V, Blackwell JM, et al
     Identification and Treatment of Lung Cancer Oncogenic Drivers in a Diverse Safety Net Setting.
     Clin Lung Cancer. 2024 Aug 31:S1525-7304(24)00192.
     PubMed     Abstract available
     
     
     
160. KAPP CM, Green C, Thiboutot J, Kim J, et al
     Understanding the Social Risk Factors That Avert Equitable Lung Cancer Care.
     Clin Lung Cancer. 2024 Aug 31:S1525-7304(24)00190.
     PubMed     Abstract available
     
     
     
161. WU J, Thomas T, Tavalire HF, Vecchio F, et al
     Letter to the Editor in Response to "Adherence to Annual Lung Cancer Screening in a Centralized Academic Program".
     Clin Lung Cancer. 2024 Aug 30:S1525-7304(24)00181.
     PubMed    
     
     
     
162. TISSERA S, Billah B, Brand M, Karim MN, et al
     Stage-Specific Guideline Concordant Treatment Impacts on Survival in Nonsmall Cell Lung Cancer: A Novel Quality Indicator.
     Clin Lung Cancer. 2024 Aug 24:S1525-7304(24)00191.
     PubMed     Abstract available
     
     
     
163. OHRI N, Bodner W, Garg M, Stiles B, et al
     Untapping the Prognostic Value of Patient-Generated Health Data in Locally Advanced Non-small Cell Lung Cancer.
     Clin Lung Cancer. 2024 Aug 23:S1525-7304(24)00182.
     PubMed     Abstract available
     
     
     
164. ZENG H, Hendriks LEL, Belderbos J, Brandts L, et al
     Association of Serum Biomarkers With Neurocognitive Decline After PCI in Small Cell Lung Cancer: An Exploratory Study of the Phase III NCT01780675 Trial.
     Clin Lung Cancer. 2024 Aug 22:S1525-7304(24)00180.
     PubMed     Abstract available
     
     
     
165. PARK JA, Yalamanchili S, Brown Z, Myers A, et al
     Implementation of an Electronic Medical Record Alert Significantly Increases Lung Cancer Screening Uptake.
     Clin Lung Cancer. 2024 Aug 18:S1525-7304(24)00157.
     PubMed     Abstract available
     
     
     
166. PAN H, Luo Q
     "Video Assisted Thoracoscopic Surgery Versus Thoracotomy Following Neoadjuvant Immunochemotherapy in Resectable Stage III Non-Small Cell Lung Cancer Among Chinese Population: A Multicenter Retrospective Cohort Study".
     Clin Lung Cancer. 2024 Aug 17:S1525-7304(24)00179.
     PubMed    
     
     
     
167. QASIM R, Riaz Z
     Video Assisted Thoracoscopic Surgery Versus Thoracotomy Following Neoadjuvant Immunochemotherapy in Resectable Stage III Non-Small Cell Lung Cancer Among Chinese Population: A Multicenter Retrospective Cohort Study.
     Clin Lung Cancer. 2024 Aug 16:S1525-7304(24)00178.
     PubMed    
     
     
     
168. LIU J, Yang Y, Wu D, Li H, et al
     Efficacy of Prophylactic Cranial Irradiation in Early to Mid-stage Small Cell Lung Cancer Patients in the Era of Magnetic Resonance Imaging.
     Clin Lung Cancer. 2024 Aug 13:S1525-7304(24)00160.
     PubMed     Abstract available
     
     
     
169. BESTVINA CM, Hara JHL, Karrison T, Bowar B, et al
     DARES: A Phase II Trial of Durvalumab and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer.
     Clin Lung Cancer. 2024 Aug 13:S1525-7304(24)00159.
     PubMed     Abstract available
     
     
     
170. SOTO-LANZA F, Glick L, Chan C, Zhong L, et al
     Long-Term Clinical, Radiological, and Mortality Outcomes Following Pneumonitis in Nonsmall Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Analysis.
     Clin Lung Cancer. 2024 Aug 3:S1525-7304(24)00155.
     PubMed     Abstract available
     
     
     
171. JIANG H, Sun N, Li R, Guan W, et al
     Evaluating Safety and Clinical Activity of Front-line Treatment with Cadonilimab plus Chemotherapy in Advanced/Metastatic Nonsmall Cell Lung Cancer Harboring STK11 Genetic Aberration: A Protocol of Phase II Study.
     Clin Lung Cancer. 2024 Aug 1:S1525-7304(24)00143.
     PubMed     Abstract available
     
     
     July 2024
172. MA J, Peng M, Bi J, Chen Q, et al
     Single-drug Chemotherapy Plus Immunotherapy as First-line Treatment for Stage ? Non-small Cell Lung Cancer Elderly Patients: A Phase II Clinical Trial UNICORN Study.
     Clin Lung Cancer. 2024 Jul 27:S1525-7304(24)00144.
     PubMed     Abstract available
     
     
     
173. KAWACHI H, Tamiya M, Oya Y, Saito G, et al
     Real-World Outcomes of Subsequent Chemotherapy after Progression Following Chemoradiation and Consolidative Durvalumab Therapy in Locally Advanced Non-small Cell Lung Cancer: An Exploratory Analysis from the CRIMSON Study (HOPE-005).
     Clin Lung Cancer. 2024 Jul 25:S1525-7304(24)00152.
     PubMed     Abstract available
     
     
     
174. REYES A, Afkhami M, Massarelli E, Fricke J, et al
     RBM10 Mutation as a Potential Negative Prognostic/Predictive Biomarker to Therapy in Non-Small-Cell Lung Cancer.
     Clin Lung Cancer. 2024 Jul 23:S1525-7304(24)00148.
     PubMed     Abstract available
     
     
     
175. AVANCINI A, Giannarielli D, Belluomini L, Schena F, et al
     Physical Exercise During Neoadjuvant Treatments for Non-Small Cell Lung Cancer: The Time is Coming.
     Clin Lung Cancer. 2024 Jul 23:S1525-7304(24)00153.
     PubMed    
     
     
     
176. ACKER F, Klein A, Rasokat A, Eisert A, et al
     Multicenter Real-World Analysis of Combined MET and EGFR Inhibition in Patients With Non-Small Cell Lung Cancer and Acquired MET Amplification or Polysomy After EGFR Inhibition.
     Clin Lung Cancer. 2024 Jul 23:S1525-7304(24)00151.
     PubMed     Abstract available
     
     
     
177. JHA P, Joshi A, Mishra R, Biswal RP, et al
     Landscape of Clinically Relevant Genomic Alterations in the Indian Non-small Cell Lung Cancer Patients.
     Clin Lung Cancer. 2024 Jul 22:S1525-7304(24)00149.
     PubMed     Abstract available
     
     
     
178. SOMISETTY M, Mack PC, Hsu CY, Huang Y, et al
     Characteristics of Lung Cancer Patients With Asymptomatic or Undiagnosed SARS-CoV-2 Infections.
     Clin Lung Cancer. 2024 Jul 20:S1525-7304(24)00145.
     PubMed     Abstract available
     
     
     
179. BENNATI C, Ferrara R, Sangaletti S, Tamberi S, et al
     The EXcellenT Trial: Exercise in Extended Oncogene Addicted Lung Cancer in Active Treatment.
     Clin Lung Cancer. 2024 Jul 15:S1525-7304(24)00146.
     PubMed     Abstract available
     
     
     
180. ZHAO JY, Presley C, Madariaga ML, Ferguson M, et al
     Prehabilitation for Older Adults Undergoing Lung Cancer Surgery: A Literature Review and Needs Assessment.
     Clin Lung Cancer. 2024 Jul 10:S1525-7304(24)00142.
     PubMed     Abstract available
     
     
     
181. KAKIUCHI Y, Saruwatari K, Murotani K, Tokito T, et al
     Real-World Efficacy and Safety of Durvalumab Administration Following Chemoradiotherapy in Elderly Patients With Unresectable Locally Advanced Nonsmall Cell Lung Cancer: A Multicenter, Retrospective Study.
     Clin Lung Cancer. 2024 Jul 6:S1525-7304(24)00139.
     PubMed     Abstract available
     
     
     
182. GANDARA DR, Subramanian J, Santos ES, Brody Y, et al
     Impact of PROphet Test in Changing Physicians' Therapeutic Decision-Making for Checkpoint Immunotherapy in Non-Small-Cell Lung Cancer.
     Clin Lung Cancer. 2024 Jul 2:S1525-7304(24)00138.
     PubMed     Abstract available
     
     
     
183. SHIBAHARA D, Tanaka K, Togao O, Shiraishi Y, et al
     Bevacizumab for Brain Radiation Necrosis in Patients With Nonsquamous Nonsmall Cell Lung Cancer.
     Clin Lung Cancer. 2024 Jul 2:S1525-7304(24)00135.
     PubMed    
     
     
     
184. SHARMA P, Mahadevia H, Donepudi S, Kujtan L, et al
     A Novel EGFR Germline Mutation in Lung Adenocarcinoma: Case Report and Literature Review.
     Clin Lung Cancer. 2024;25:479-482.
     PubMed    
     
     
     
185. KUDO Y, Nakamura T, Matsubayashi J, Ichinose A, et al
     AI-driven Characterization of Solid Pulmonary Nodules on CT Imaging for Enhanced Malignancy Prediction in Small-sized Lung Adenocarcinoma.
     Clin Lung Cancer. 2024;25:431-439.
     PubMed     Abstract available
     
     
     
186. PETRINI I, Bruno R, Di Stefano I, Aprile V, et al
     A patient with a Germline (p.R776H) EGFR Mutation With Multiple Lung Cancers Harboring Different Somatic EGFR Mutations.
     Clin Lung Cancer. 2024;25:e238-e242.
     PubMed    
     
     
     June 2024
187. RECK M, De T, Paz-Ares L, Edmondson-Jones M, et al
     Treatment-Switching Adjustment of Overall Survival in CheckMate 227 Part 1 Evaluating First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy for Metastatic Nonsmall Cell Lung Cancer.
     Clin Lung Cancer. 2024 Jun 29:S1525-7304(24)00131.
     PubMed     Abstract available
     
     
     
188. KELTNER S, Esslinger H, Wu X, Rai S, et al
     Refining Surveillance Guidelines after Stereotactic Body Radiation Therapy for Early-Stage Lung Cancer.
     Clin Lung Cancer. 2024 Jun 21:S1525-7304(24)00134.
     PubMed     Abstract available
     
     
     
189. SHAH AT, Blanchard I, Padda SK, Wakelee HA, et al
     Molecular Characteristics and Pretreatment Neutrophil-to-Lymphocyte Ratio as Predictors of Durable Clinical Benefit from Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer.
     Clin Lung Cancer. 2024 Jun 19:S1525-7304(24)00133.
     PubMed     Abstract available
     
     
     
190. ZHANG Y, Chen Z, Chen G, Huang Y, et al
     The Design for a Phase II, Randomized, Multicenter Study of CtDNA-Guided Treatment With Furmonertinib Combined Therapy or Furmonertinib Alone for Untreated Advanced EGFR Mutant Non-small-cell Lung Cancer Patients: The FOCUS-C Study.
     Clin Lung Cancer. 2024 Jun 10:S1525-7304(24)00111.
     PubMed     Abstract available
     
     
     
191. MUSCOLINO P, Scimone C, Sapuppo E, Micali V, et al
     Gefitinib Resensitization After a TKI-Free Interval in Osimertinib Resistant Non-Small-Cell Lung Cancer: A Glimpse of Hope in Time of Crisis?
     Clin Lung Cancer. 2024 Jun 10:S1525-7304(24)00112.
     PubMed    
     
     
     
192. WU X, Stabile LP, Burns TF
     The Emerging Role of Immune Checkpoint Blockade for the Treatment of Lung Cancer Brain Metastases.
     Clin Lung Cancer. 2024 Jun 10:S1525-7304(24)00124.
     PubMed     Abstract available
     
     
     
193. ROBINSON LA, Tanvetyanon T, Robinson NA, Bryant S, et al
     Surgery and Stereotactic Radiotherapy for Stage I Small-Cell Lung Carcinoma: A 25-Year Experience.
     Clin Lung Cancer. 2024 Jun 8:S1525-7304(24)00110.
     PubMed     Abstract available
     
     
     
194. GALLINA FT, Chiappetta M, Taje R, Forcella D, et al
     Neutrophil-to-Lymphocyte Ratio and Risk of Nodal Metastasis in Early-Stage Lung Adenocarcinoma: A Brief Report From a Multicentric Analysis.
     Clin Lung Cancer. 2024;25:e196-e200.
     PubMed    
     
     
     
195. PARK JE, Hong KS, Choi SH, Lee SY, et al
     Durvalumab Consolidation After Chemoradiotherapy in Elderly Patients With Unresectable Stage III NSCLC: A Real-World Multicenter Study.
     Clin Lung Cancer. 2024;25:354-364.
     PubMed     Abstract available
     
     
     
196. WU E, Reznicek J, Yeldandi AV, Patel JD, et al
     Neoadjuvant Therapy Before Resection of Primary Pulmonary Lymphoepithelial Carcinoma.
     Clin Lung Cancer. 2024;25:376-379.
     PubMed    
     
     
     
197. FENG A, Huang Y, Zeng Y, Shao Y, et al
     Improvement of Prediction Performance for Radiation Pneumonitis by Using 3-Dimensional Dosiomic Features.
     Clin Lung Cancer. 2024;25:e173-e180.
     PubMed     Abstract available
     
     
     May 2024
198. AWIDI M, Mier-Hicks A, Perimbeti S, Attwood K, et al
     Patients' Preferences for Adjuvant Osimertinib in Non-Small-Cell Lung Cancer After Complete Surgical Resection: What Makes It Worth It to Patients?
     Clin Lung Cancer. 2024 May 29:S1525-7304(24)00082.
     PubMed     Abstract available
     
     
     
199. CHRISTENSEN NL, Gouliaev A, McPhail S, Lyratzopoulos G, et al
     Routes to Diagnosis in Danish Lung Cancer Patients: Emergency Presentation, Age and Smoking History-A Population-Based Cohort Study.
     Clin Lung Cancer. 2024 May 25:S1525-7304(24)00108.
     PubMed     Abstract available
     
     
     
200. KLEEMISS M, Muller CE, Schneider M, Strotmann R, et al
     Tepotinib in a Patient With Advanced Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Undergoing Concomitant Hemodialysis for Renal Failure: A Case Report.
     Clin Lung Cancer. 2024 May 25:S1525-7304(24)00109.
     PubMed    
     
     
     
201. THOSANI DS, Meredith LT, West R, Till BM, et al
     Association Between Utilization of Services and Perioperative Outcomes for Lung Cancer Resection.
     Clin Lung Cancer. 2024 May 20:S1525-7304(24)00097.
     PubMed     Abstract available
     
     
     
202. ROUSSEAU G, Dantoing E, Leturgie B, Tillon-Strozyk J, et al
     Brief Report: Carboplatin, Weekly Paclitaxel and Pembrolizumab in Elderly Patients for Advanced Non-Small Cell Lung Cancer With PD-L1 < 50%: Real-World Data.
     Clin Lung Cancer. 2024 May 18:S1525-7304(24)00084.
     PubMed    
     
     
     
203. IWAI C, Jo T, Konishi T, Fujita A, et al
     Interstitial Pneumonitis Following Sequential Administration of Programmed Death-1/Programmed Death-Ligand1 Inhibitors and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors For Non-Small Cell Lung Cancer: A Matched-Pair Cohort Study Using a
     Clin Lung Cancer. 2024 May 11:S1525-7304(24)00067.
     PubMed     Abstract available
     
     
     
204. MINNE RL, Luo NY, Traynor AM, Huang M, et al
     Genomic and Immune Landscape Comparison of MET Exon 14 Skipping and MET-Amplified Non-small Cell Lung Cancer.
     Clin Lung Cancer. 2024 May 10:S1525-7304(24)00080.
     PubMed     Abstract available
     
     
     
205. TAYLOR M, Evison M, Michael S, Obale E, et al
     Pre-Operative Measures of Systemic Inflammation Predict Survival After Surgery for Primary Lung Cancer.
     Clin Lung Cancer. 2024 May 8:S1525-7304(24)00077.
     PubMed     Abstract available
     
     
     
206. ZHANG W, Tian S, Li X, Chen Y, et al
     ETV6-NTRK2 Fusion in a Patient With Metastatic Pulmonary Atypical Carcinoid Successfully Treated With Entrectinib: A Case Report and Review of the Literature.
     Clin Lung Cancer. 2024;25:215-224.
     PubMed     Abstract available
     
     
     
207. TILL BM, Grenda T, Tidwell T, Wickes B, et al
     Brief Report: Nonmalignant Surgical Resection Among Individuals with Screening-Detected Versus Incidental Lung Nodules.
     Clin Lung Cancer. 2024;25:e129-e132.
     PubMed    
     
     
     April 2024
208. SRIDHAR A, West HJ, Singhi EK
     Brief Report on Global Clinician Practices in the First-Line Management of Metastatic Non-Small Cell Lung Cancer.
     Clin Lung Cancer. 2024 Apr 30:S1525-7304(24)00068.
     PubMed     Abstract available
     
     
     
209. TANVETYANON T, Chen DT, Gray JE
     Timeliness of EGFR/ALK Inhibitor Treatment and Survival in Lung Cancer: A Population-Based Analysis.
     Clin Lung Cancer. 2024 Apr 30:S1525-7304(24)00078.
     PubMed     Abstract available
     
     
     
210. LU S, Zhou Q, Liu X, Du Y, et al
     Updated Efficacy and Safety of Lorlatinib in a Phase 2 Study in Chinese Patients With Previously Treated Advanced ALK-Positive Non-small Cell Lung Cancer.
     Clin Lung Cancer. 2024 Apr 30:S1525-7304(24)00079.
     PubMed     Abstract available
     
     
     
211. WONG LY, Choudhary S, Kapula N, Lin M, et al
     Barriers to Completing Low Dose Computed Tomography Scan for Lung Cancer Screening.
     Clin Lung Cancer. 2024 Apr 27:S1525-7304(24)00070.
     PubMed     Abstract available
     
     
     
212. NONAKA Y, Isaka M, Matsushima K, Katsumata S, et al
     Prediction of Pleural Lavage Cytology According to Thin-Section Computed Tomography in Non-Small-Cell Lung Cancer.
     Clin Lung Cancer. 2024 Apr 16:S1525-7304(24)00053.
     PubMed     Abstract available
     
     
     
213. FANTONI A, Warburton L, Solomon B, Alexander M, et al
     Completion of Pembrolizumab in Advanced Non-Small Cell Lung Cancer-Real World Outcomes After Two Years of Therapy (COPILOT).
     Clin Lung Cancer. 2024 Apr 15:S1525-7304(24)00051.
     PubMed     Abstract available
     
     
     
214. JIANG Z, Li Q, Ruan J, Li Y, et al
     Machine Learning-Based Prediction of Pathological Responses and Prognosis After Neoadjuvant Chemotherapy for Non-Small-Cell Lung Cancer: A Retrospective Study.
     Clin Lung Cancer. 2024 Apr 12:S1525-7304(24)00049.
     PubMed     Abstract available
     
     
     
215. ORDING AG, Christensen TD, Skjoth F, Noble S, et al
     Risk of Venous Thromboembolism in Patients With Stage III and IV Non-Small-Cell Lung Cancer: Nationwide Descriptive Cohort Study.
     Clin Lung Cancer. 2024 Apr 11:S1525-7304(24)00047.
     PubMed     Abstract available
     
     
     
216. NILSSEN Y, Brustugun OT, Fjellbirkeland L, Gronberg BH, et al
     Small Cell Lung Cancer in Norway: Patterns of Care by Health Region and Survival Trends.
     Clin Lung Cancer. 2024 Apr 10:S1525-7304(24)00046.
     PubMed     Abstract available
     
     
     
217. MILLS MN, Uno A, Li P, Liveringhouse C, et al
     Clinical Outcomes of Patients with Non-Small Cell Lung Cancer Leptomeningeal Disease Following Receipt of EGFR-Targeted Therapy, Immune-Checkpoint Blockade, Intrathecal Chemotherapy, or Radiation Therapy Alone.
     Clin Lung Cancer. 2024 Apr 10:S1525-7304(24)00048.
     PubMed     Abstract available
     
     
     
218. ROBERTS HN, Solomon B, Harden S, Lingaratnam S, et al
     Utility of 30-Day Mortality Following Systemic Anti-Cancer Treatment as a Quality Indicator in Advanced Lung Cancer.
     Clin Lung Cancer. 2024 Apr 6:S1525-7304(24)00045.
     PubMed     Abstract available
     
     
     
219. PAN H, Chen H, Kong W, Ning J, et al
     Video-Assisted Thoracoscopic Surgery Versus Thoracotomy Following Neoadjuvant Immunochemotherapy in Resectable Stage III Non-Small Cell Lung Cancer Among Chinese Populations: A Multi-Center Retrospective Cohort Study.
     Clin Lung Cancer. 2024 Apr 2:S1525-7304(24)00042.
     PubMed     Abstract available
     
     
     March 2024
220. DONINGTON J, Hu X, Zhang S, Song Y, et al
     Real-World Neoadjuvant Treatment Patterns and Outcomes in Resected Non-Small-Cell Lung Cancer.
     Clin Lung Cancer. 2024 Mar 22:S1525-7304(24)00041.
     PubMed     Abstract available
     
     
     
221. DJUNADI TA, Oh Y, Lee J, Yu J, et al
     Redefining Clinical Hyperprogression: The Incidence, Clinical Implications, and Risk Factors of Hyperprogression in Non-Small Cell Lung Cancer Treated with Immunotherapy.
     Clin Lung Cancer. 2024 Mar 16:S1525-7304(24)00036.
     PubMed     Abstract available
     
     
     
222. GARON EB, Cho BC, Luft A, Alatorre-Alexander J, et al
     A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study.
     Clin Lung Cancer. 2024 Mar 15:S1525-7304(24)00038.
     PubMed    
     
     
     
223. MARMARELIS ME, Scholes DG, McGrath CM, Priore SF, et al
     Brief Report: Impact of Reflex Testing on Tissue-Based Molecular Genotyping in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer.
     Clin Lung Cancer. 2024 Mar 12:S1525-7304(24)00037.
     PubMed    
     
     
     
224. NOURMOHAMMADI N, Liang THP, Sadigh G
     Patient-Provider Lung Cancer Screening Discussions: An Analysis of a National Survey.
     Clin Lung Cancer. 2024 Mar 2:S1525-7304(24)00034.
     PubMed     Abstract available
     
     
     
225. MOGHANAKI D, Taylor J, Bryant AK, Vitzthum LK, et al
     Lung Cancer Survival Trends in the Veterans Health Administration.
     Clin Lung Cancer. 2024 Mar 2:S1525-7304(24)00035.
     PubMed     Abstract available
     
     
     
226. ARDESHIR-LARIJANI F, Maniar R, Goyal S, Loehrer PJ, et al
     Trop-2 Expression and Its Impact on Survival in Thymic Epithelial Tumors: Brief Report.
     Clin Lung Cancer. 2024;25:180-185.
     PubMed    
     
     
     
227. JENNINGS EM, Camidge DR, Gadgeel S, Barker S, et al
     Trial Design and Optimal Determination of CNS Activity of Small Molecule Targeted Therapy in NSCLC.
     Clin Lung Cancer. 2024;25:91-99.
     PubMed     Abstract available
     
     
     
228. VERMA S, Young S, Kennedy TAC, Carvalhana I, et al
     Detection of Circulating Tumor DNA After Stereotactic Ablative Radiotherapy in Patients With Unbiopsied Lung Tumors (SABR-DETECT).
     Clin Lung Cancer. 2024;25:e87-e91.
     PubMed     Abstract available
     
     
     
229. GONZALEZ-MOSQUERA LF, Rous FA, Rogers A, Smith N, et al
     ALK Rearrangement Positive Lung Adenocarcinoma in Pregnancy Treated With Alectinib: A Case Report.
     Clin Lung Cancer. 2024;25:e77-e80.
     PubMed     Abstract available
     
     
     
230. BORGHETTI P, Facheris G, Ciammella P, Galaverni M, et al
     Sterotactic Ablative Radiotherapy in a Multicentric Series of Oligometastatic SCLC: The SAMOS Cohort.
     Clin Lung Cancer. 2024;25:151-158.
     PubMed     Abstract available
     
     
     
231. INNO A, Picece V, Bogina G, Settanni G, et al
     Niraparib for the Treatment of Metastatic NSCLC in a Patient With BRCA2 Germinal Mutation: A Case Report.
     Clin Lung Cancer. 2024;25:175-179.
     PubMed    
     
     
     February 2024
232. GEORGE B, Baydoun A, Bhat S, Bailey L, et al
     Invasive Nodal Staging via Endobronchial Ultrasound and Outcome in Patients Treated with Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer - Results from a Single Institution Study.
     Clin Lung Cancer. 2024 Feb 24:S1525-7304(24)00030.
     PubMed     Abstract available
     
     
     
233. KHOKHAR B, Chiang B, Iglay K, Reynolds K, et al
     QT-Interval Prolongation, Torsades de Pointes, and Heart Failure With EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Systematic Review.
     Clin Lung Cancer. 2024 Feb 17:S1525-7304(24)00016.
     PubMed     Abstract available
     
     
     
234. PONVILAWAN B, Mahadevia H, Qasim H, Sharma P, et al
     Brief Report: Evaluating the Impact of Perioperative Immune Checkpoint Inhibitor in the Treatment of Patients with Resectable Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
     Clin Lung Cancer. 2024 Feb 15:S1525-7304(24)00014.
     PubMed    
     
     
     
235. D'AIELLO A, Stiles B, Ohri N, Levy B, et al
     Perioperative Immunotherapy for Non-Small Cell Lung Cancer: Practical Application of Emerging Data and New Challenges.
     Clin Lung Cancer. 2024 Feb 13:S1525-7304(24)00015.
     PubMed     Abstract available
     
     
     
236. WU Y, Zhao Y, Wu Y, Chen H, et al
     A Retrospective Real-World Study of Prognostic Factors Associated With EGFR Mutated Lung Cancer With Leptomeningeal Metastasis.
     Clin Lung Cancer. 2024 Feb 8:S1525-7304(24)00012.
     PubMed     Abstract available
     
     
     
237. OKUMA Y, Shintani Y, Sekine I, Shukuya T, et al
     Efficacy of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Metastatic Non-Small Cell Lung Cancer Patients with Poor Performance Status and Epidermal Growth Factor Receptor Mutations: Findings from the Japanese Lung Cancer Registry Data
     Clin Lung Cancer. 2024 Feb 2:S1525-7304(24)00007.
     PubMed     Abstract available
     
     
     January 2024
238. FIROZ WA, Sen F, Kiuru M, Huang V, et al
     A Case of ROS1-Fusion Non-Small Cell Lung Cancer with Acquired BRAF Mutation Developing Unusual Skin Metastasis.
     Clin Lung Cancer. 2024 Jan 30:S1525-7304(24)00011.
     PubMed    
     
     
     
239. MATSUBARA T, Yamaguchi M, Shimokawa M, Okamoto I, et al
     Phase II Trial of Adjuvant Atezolizumab Therapy in Elderly Patients with Completely Resected Stage II/III Non-Small Cell Lung Cancer: RELIANCE Trial.
     Clin Lung Cancer. 2024 Jan 28:S1525-7304(24)00010.
     PubMed     Abstract available
     
     
     
240. KAMIGAICHI A, Hamada A, Tsuboi M, Yoshimura K, et al
     A Multi-Institutional, Randomized, Phase III Trial Comparing Anatomical Segmentectomy and Lobectomy for Clinical Stage IA3 Pure-Solid Non-Small-Cell Lung Cancer: West Japan Oncology Group Study WJOG16923L (STEP UP Trial).
     Clin Lung Cancer. 2024 Jan 26:S1525-7304(24)00006.
     PubMed     Abstract available
     
     
     
241. TSUBOKAWA N, Mimae T, Mimura T, Kamigaichi A, et al
     Clinical Significance of Preserving Pulmonary Function After Lung Resection in Early-Stage Non-Small-Cell Lung Cancer.
     Clin Lung Cancer. 2024 Jan 26:S1525-7304(24)00005.
     PubMed     Abstract available
     
     
     
242. WALIANY S, Neal JW, Engel-Nitz N, Lam C, et al
     HER2-Mutant Advanced and/or Metastatic Non-Small-Cell Lung Cancer: A US Electronic Health Records Database Analysis of Clinical Characteristics, Treatment Practice Patterns, and Outcomes.
     Clin Lung Cancer. 2024 Jan 18:S1525-7304(24)00004.
     PubMed     Abstract available
     
     
     
243. RODRIGUEZ-ABREU D, Bosch-Barrera J, Gray JE, Ahn MJ, et al
     STAR-121: A Phase III Randomized Study of Domvanalimab and Zimberelimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Untreated Metastatic Non-Small Cell Lung Cancer With No Actionable Gene Alterations.
     Clin Lung Cancer. 2024 Jan 6:S1525-7304(23)00267.
     PubMed     Abstract available
     
     
     
244. CHEN Q, Wang J, Wang X, Yin Y, et al
     Influence of Tumor Cavitation on Assessing the Clinical Benefit of Anti-PD1 or PD-L1 Inhibitors in Advanced Lung Squamous Cell Carcinoma.
     Clin Lung Cancer. 2024;25:29-38.
     PubMed     Abstract available
     
     
     
245. MAO S, Rosner S, Forde PM, Chaft JE, et al
     A Brief Report on the Patterns of Mediastinal Nodal Failure in Resectable Stage IB-IIIA NSCLC Treated With Neoadjuvant Immunotherapy Combinations, a Secondary Analysis of a Prospective Trial.
     Clin Lung Cancer. 2024;25:e67-e71.
     PubMed    
     
     
     
246. HAYASAKA K, Takeda H, Sakurada A, Matsumura Y, et al
     Clinical, Genomic, and Transcriptomic Featurses of Lung Adenocarcinoma With Uncommon EGFR Mutation.
     Clin Lung Cancer. 2024;25:e43-e51.
     PubMed     Abstract available
     
     
     
247. ORLANDI R, Leuzzi G, Rolli L, Ferrari M, et al
     Long-Term Survival Analysis of Pleural Mesothelioma Patients Undergoing Surgery: Brief Report From a Tertiary Referral Centre.
     Clin Lung Cancer. 2024;25:e5-e10.
     PubMed     Abstract available
     
     
     
248. GAO M, Wang L, Jing F, Zhang F, et al
     The Efficacy of Pemigatinib in Advanced NSCLC With FGFR Aberration: Case Report.
     Clin Lung Cancer. 2024;25:e62-e66.
     PubMed    
     
     
     
249. KASHIZAKI F, Chen H, Miyasaka A, Tsuchiya N, et al
     Safety of Readministration of EGFR-TKI After Onset of Interstitial Lung Disease in Advanced EGFR-Mutated NSCLC: A Systematic Review and Meta-Analysis.
     Clin Lung Cancer. 2024;25:e52-e57.
     PubMed     Abstract available
     
     
     
250. JURICA JM, Carsten B, Balakhani S, Haag MM, et al
     CSF Cytology Identifies Mechanisms of Tyrosine Kinase Inhibitor Resistance in Patient With EGFR-Mutated NSCLC With CNS Progression.
     Clin Lung Cancer. 2024;25:77-79.
     PubMed    
     
     
     
251. SOO RA, de Marinis F, Han JY, Ho JC, et al
     TARGET: A Phase II, Open-Label, Single-Arm Study of 5-Year Adjuvant Osimertinib in Completely Resected EGFR-Mutated Stage II to IIIB NSCLC Post Complete Surgical Resection.
     Clin Lung Cancer. 2024;25:80-84.
     PubMed     Abstract available
     
     
     
252. LU K, Woodward BD, Boys J, Onaitis M, et al
     Brief Report: Evaluation of Molecular Profiling Strategies for Neoadjuvant Osimertinib in Stage IIIA EGFR-Mutant NSCLC.
     Clin Lung Cancer. 2024;25:e58-e61.
     PubMed    
     
     
     
253. FRIEDES C, Yegya-Raman N, Zhang S, Iocolano M, et al
     Patterns of Failure in Metastatic NSCLC Treated With First Line Pembrolizumab and Use of Local Therapy in Patients With Oligoprogression.
     Clin Lung Cancer. 2024;25:50-60.
     PubMed     Abstract available
     
     
     December 2023
254. DETTERBECK F, Ely S, Udelsman B, Blasberg J, et al
     So Now We Know-Reflections on the Extent of Resection for Stage I Lung Cancer.
     Clin Lung Cancer. 2023 Dec 28:S1525-7304(23)00262.
     PubMed     Abstract available
     
     
     
255. JANG C, Lau SC, Velcheti V
     To Crush or Not to Crush: Administering Dabrafenib and Trametinib Through a Nasogastric Tube in a Critically Ill Patient With Nonsmall Cell Lung Cancer - A Case Report and Review of Literature of Targeted Therapies Given Through Enteral Feeding Tubes.
     Clin Lung Cancer. 2023 Dec 27:S1525-7304(23)00270.
     PubMed     Abstract available
     
     
     
256. RAMANATHAN S, Hochstedler KA, Laucis AM, Movsas B, et al
     Predictors of Early Hospice or Death in Patients With Inoperable Lung Cancer Treated With Curative Intent.
     Clin Lung Cancer. 2023 Dec 27:S1525-7304(23)00283.
     PubMed     Abstract available
     
     
     
257. BARSOUK A, Friedes C, Iocolano M, Doucette A, et al
     Plunging Into the PACIFIC: Outcomes of Patients With Unresectable KRAS-Mutated Non-Small Cell Lung Cancer Following Definitive Chemoradiation and Durvalumab Consolidation.
     Clin Lung Cancer. 2023 Dec 22:S1525-7304(23)00266.
     PubMed     Abstract available
     
     
     
258. PRELAJ A, Ganzinelli M, Provenzano L, Mazzeo L, et al
     APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research.
     Clin Lung Cancer. 2023 Dec 22:S1525-7304(23)00269.
     PubMed     Abstract available
     
     
     
259. VERSCHUEREN MV, Peters BJ, Bloem LT, Kruik VR, et al
     Pembrolizumab Plus Chemotherapy Per PD-L1 Stratum In Patients With Metastatic Non-Small Cell Lung Cancer: Real-World Effectiveness Versus Trial Efficacy.
     Clin Lung Cancer. 2023 Dec 20:S1525-7304(23)00268.
     PubMed     Abstract available
     
     
     
260. PILON Y, Rokah M, Seitlinger J, Sepesi B, et al
     Transitioning to Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: Trends and Surgical Outcomes in a Regionalized Pulmonary Oncology Network.
     Clin Lung Cancer. 2023 Dec 19:S1525-7304(23)00264.
     PubMed     Abstract available
     
     
     
261. CAO J, Zhang C, Zhang X, Liu L, et al
     The Clinical Outcomes of Thoracoscopic Versus Open Lobectomy for Non-Small-Cell Lung Cancer After Neoadjuvant Therapy: A Multi-Center Retrospective Cohort Study.
     Clin Lung Cancer. 2023 Dec 16:S1525-7304(23)00263.
     PubMed     Abstract available
     
     
     
262. SCHOENMAEKERS J, Dijkstra J, van der Wekken A, Paats M, et al
     In-depth Analysis of Lorlatinib-related neurocognitive Adverse Events in Patients With Non-small-cell Lung Cancer.
     Clin Lung Cancer. 2023 Dec 13:S1525-7304(23)00261.
     PubMed     Abstract available
     
     
     
263. MATHIOT L, Nigen B, Goronflot T, Hiret S, et al
     Prognostic Impact of TP53 Mutations in Metastatic Nonsquamous Non-small-cell Lung Cancer.
     Clin Lung Cancer. 2023 Dec 13:S1525-7304(23)00260.
     PubMed     Abstract available
     
     
     
264. CALI DAYLAN AE, Maia CM, Attarian S, Guo X, et al
     HIV Associated Lung Cancer: Unique Clinicopathologic Features and Immune Biomarkers Impacting Lung Cancer Screening and Management.
     Clin Lung Cancer. 2023 Dec 12:S1525-7304(23)00259.
     PubMed     Abstract available
     
     
     
265. FAN Y, Drilon A, Chiu CH, Loong HHF, et al
     Brief Report: Updated Efficacy and Safety Data From an Integrated Analysis of Entrectinib in Locally Advanced/Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
     Clin Lung Cancer. 2023 Dec 7:S1525-7304(23)00258.
     PubMed    
     
     
     
266. OU SI, Prawitz T, Lin HM, Hong JL, et al
     Efficacy of Mobocertinib and Amivantamab in Patients With Advanced Non-Small Cell Lung Cancer With EGFR Exon 20 Insertions Previously Treated With Platinum-Based Chemotherapy: An Indirect Treatment Comparison.
     Clin Lung Cancer. 2023 Dec 4:S1525-7304(23)00254.
     PubMed     Abstract available
     
     
     
267. GROSS AJ, Sheikh S, Kharouta M, Chaung K, et al
     The Impact of Prophylactic Cranial Irradiation and Consolidative Thoracic Radiation Therapy for Extensive Stage Small-Cell Lung Cancer in the Transition to the Chemo-Immunotherapy Era: A Single Institution Series.
     Clin Lung Cancer. 2023;24:696-705.
     PubMed     Abstract available
     
     
     
268. VISONA G, Spiller LM, Hahn S, Hattingen E, et al
     Machine-Learning-Aided Prediction of Brain Metastases Development in Non-Small-Cell Lung Cancers.
     Clin Lung Cancer. 2023;24:e311-e322.
     PubMed     Abstract available
     
     
     
269. FARIA N, Lacerda C, Lopes J, Viana C, et al
     PET-CT SUV(max) and Endobronchial Ultrasound Features for Prediction of Malignancy: A Prospective Study.
     Clin Lung Cancer. 2023;24:753-760.
     PubMed     Abstract available
     
     
     
270. LI S, Chen M, Wang Y, Li X, et al
     An Effective Malignancy Prediction Model for Incidentally Detected Pulmonary Subsolid Nodules Based on Current and Prior CT Scans.
     Clin Lung Cancer. 2023;24:e301-e310.
     PubMed     Abstract available
     
     
     
271. VINDUM HH, Kristensen K, Christensen NL, Madsen HH, et al
     Outcome of Incidental Pulmonary Nodules in a Real-World Setting.
     Clin Lung Cancer. 2023;24:673-681.
     PubMed     Abstract available
     
     
     
272. GHANEM P, Murray JC, Hsu M, Guo MZ, et al
     Clinical and Genomic Characterization of Long-Term Responders Receiving Immune Checkpoint Blockade for Metastatic Non-Small-Cell Lung Cancer.
     Clin Lung Cancer. 2023 Dec 1:S1525-7304(23)00255.
     PubMed     Abstract available
     
     
     November 2023
273. PORTE M, Vaudron A, Crequit P, Vaugier L, et al
     A Multicenter Study Assessing the Real-World Use and Effectiveness of First-Line Chemotherapy Plus Immunotherapy in Advanced Small-Cell Lung Cancer (SCLC) Patients.
     Clin Lung Cancer. 2023 Nov 23:S1525-7304(23)00252.
     PubMed     Abstract available
     
     
     
274. LIU J, Xiang Y, Fang T, Zeng L, et al
     Advances in the Diagnosis and Treatment of Advanced Non-Small-Cell Lung Cancer With EGFR Exon 20 Insertion Mutation.
     Clin Lung Cancer. 2023 Nov 23:S1525-7304(23)00253.
     PubMed     Abstract available
     
     
     
275. RIUDAVETS M, Auclin E, Mosteiro M, Dempsey N, et al
     Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer.
     Clin Lung Cancer. 2023 Nov 22:S1525-7304(23)00242.
     PubMed     Abstract available
     
     
     
276. HUI C, Marquez C, Lau B, Das M, et al
     Patient Selection and Outcomes for Hypofractionated Accelerated Radiation and Concurrent Chemotherapy for Non-Small-Cell Lung Cancer.
     Clin Lung Cancer. 2023 Nov 21:S1525-7304(23)00243.
     PubMed     Abstract available
     
     
     
277. OHRI N, Chudgar NP, Vimolratana M, Cheng H, et al
     Comments on "Effect of Surgical Treatment for N2-Positive c-Stage III Non-Small Cell Lung Carcinoma in the "PACIFIC" Era".
     Clin Lung Cancer. 2023 Nov 14:S1525-7304(23)00227.
     PubMed    
     
     
     
278. HUI C, Brown E, Wong S, Das M, et al
     Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer: Protocol for a Bayesian Optimal Phase I/II Trial.
     Clin Lung Cancer. 2023 Nov 8:S1525-7304(23)00230.
     PubMed     Abstract available
     
     
     
279. SAWA K, Ihara Y, Imai T, Sugimoto A, et al
     Lack of Association Between Immunotherapy and Improvement of Survival for Non-small Cell Lung Cancer Patients With Hemodialysis: A Nationwide Retrospective Cohort Study.
     Clin Lung Cancer. 2023 Nov 7:S1525-7304(23)00229.
     PubMed     Abstract available
     
     
     
280. ADACHI H, Ito H, Isaka T, Saito H, et al
     Sufficient Multidisciplinary Discussion Can Make Patients' Outcomes Better in the Treatment for Stage III Non-Small-Cell Lung Carcinoma - Reply to Ohri et al.
     Clin Lung Cancer. 2023 Nov 3:S1525-7304(23)00228.
     PubMed    
     
     
     
281. WOLF J, Souquet PJ, Goto K, Cortot A, et al
     Improved Survival Outcomes in Patients With MET-Dysregulated Advanced NSCLC Treated With MET Inhibitors: Results of a Multinational Retrospective Chart Review.
     Clin Lung Cancer. 2023;24:641-650.
     PubMed     Abstract available
     
     
     
282. FRICKE J, Wang J, Gallego N, Mambetsariev I, et al
     Selpercatinib and Pralsetinib Induced Chylous Ascites in RET-Rearranged Lung Adenocarcinoma: A Case Series.
     Clin Lung Cancer. 2023;24:666-671.
     PubMed    
     
     
     
283. MALLAEV M, Chirindel AF, Lardinois D, Tamm M, et al
     3D-Quantitated Single Photon Emission Computed Tomography/Computed Tomography: Impact on intended Management Compared to Lung Perfusion Scan in Marginal Candidates for Pulmonary Resection.
     Clin Lung Cancer. 2023;24:621-630.
     PubMed     Abstract available
     
     
     
284. LEE KH, Chung JH, Cho S, Lee JS, et al
     Differential Prognostic Value of Vascular Invasion in Resected Lung Adenocarcinomas According to Epidermal Growth Factor Receptor Mutational Status.
     Clin Lung Cancer. 2023;24:e291-e299.
     PubMed     Abstract available
     
     
     
285. ASAO T, Shukuya T, Mimori T, Goto Y, et al
     Study Design and Rationale for Marble Study: A Phase II Trial of Atezolizumab (MPDL3280A) Plus Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Thymic Carcinoma (JTD2101).
     Clin Lung Cancer. 2023;24:e247-e253.
     PubMed     Abstract available
     
     
     October 2023
286. PIRZADEH M, Lagina M, Wood C, Valley T, et al
     Barriers to Timely Lung Cancer Care in Early Stage Non-Small Cell Lung Cancer and Impact on Patient Outcomes.
     Clin Lung Cancer. 2023 Oct 31:S1525-7304(23)00226.
     PubMed     Abstract available
     
     
     
287. QIN A, Wells L, Malhotra B, Gadgeel S, et al
     A Phase II Trial of Pevonedistat and Docetaxel in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.
     Clin Lung Cancer. 2023 Oct 26:S1525-7304(23)00224.
     PubMed     Abstract available
     
     
     
288. FLOREZ N, Kiel L, Riano I, Patel S, et al
     Lung Cancer in Women: The Past, Present, and Future.
     Clin Lung Cancer. 2023 Oct 20:S1525-7304(23)00212.
     PubMed     Abstract available
     
     
     
289. ADACHI H, Morohoshi T, Shintani Y, Okami J, et al
     Benefit of Adjuvant Chemotherapy for Patients Older Than 75 Years With Completely Resected p-Stage II-IIIA Non-Small-Cell Lung Cancer: A Retrospective Cohort Study Using Japanese Nationwide Real-World Data.
     Clin Lung Cancer. 2023 Oct 12:S1525-7304(23)00192.
     PubMed     Abstract available
     
     
     
290. ENJO-BARREIRO JR, Ruano-Ravina A, Perez-Rios M, Kelsey K, et al
     Genome Wide Association Studies in Small-Cell Lung Cancer. A Systematic Review.
     Clin Lung Cancer. 2023 Oct 12:S1525-7304(23)00195.
     PubMed     Abstract available
     
     
     
291. YU LEE-MATEUS A, Sawal N, Hartley C, Edell E, et al
     Efficacy of Robotic Bronchoscopy for Molecular Marker Analysis in Primary Lung Cancer.
     Clin Lung Cancer. 2023 Oct 12:S1525-7304(23)00194.
     PubMed     Abstract available
     
     
     
292. LEE G, Hill LP, Schroeder MC, Kraus SJ, et al
     Adherence to Annual Lung Cancer Screening in a Centralized Academic Program.
     Clin Lung Cancer. 2023 Oct 12:S1525-7304(23)00193.
     PubMed     Abstract available
     
     
     
293. ZHANG JT, Dong S, Gu WQ, Zhao N, et al
     Adjuvant Therapy-Free Strategy for Stage IB to IIIA Non-Small-Cell Lung Cancer Patients After Radical Resection Based on Longitudinal Undetectable Molecular Residual Disease: Prospective, Multicenter, Single-Arm Study (CTONG 2201).
     Clin Lung Cancer. 2023 Oct 6:S1525-7304(23)00189.
     PubMed     Abstract available
     
     
     
294. KOBAT H, Elkonaissi I, Foreman E, Davidson M, et al
     Smoking, Diabetes Mellitus, and Previous Cardiovascular Disease as Predictors of Anticancer Treatment-Induced Cardiotoxicity in Non-Small-Cell Lung Cancer: A Real-World Study.
     Clin Lung Cancer. 2023 Oct 4:S1525-7304(23)00187.
     PubMed     Abstract available
     
     
     
295. NAKAMICHI S, Kubota K, Matsuyama K, Misumi T, et al
     A Phase ? Study of Ubenimex Combined With Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non-Small-Cell Lung Cancer: TORG2241 (UBE-Q).
     Clin Lung Cancer. 2023 Oct 4:S1525-7304(23)00186.
     PubMed     Abstract available
     
     
     September 2023
296. DESAI A, Smith CJ, Ashara Y, Orme JJ, et al
     Real-World Outcomes With Lurbinectedin in Second-Line Setting and Beyond for Extensive Stage Small Cell Lung Cancer.
     Clin Lung Cancer. 2023 Sep 17:S1525-7304(23)00183.
     PubMed     Abstract available
     
     
     
297. TAKADA K, Takamori S, Brunetti L, Crucitti P, et al
     Impact of Neoadjuvant Immune Checkpoint Inhibitors on Surgery and Perioperative Complications in Patients With Non-small-cell Lung Cancer: A Systematic Review.
     Clin Lung Cancer. 2023 Sep 3:S1525-7304(23)00182.
     PubMed     Abstract available
     
     
     August 2023
298. BOCHTLER T, Christopoulos P, Schlamp K, Winkler F, et al
     Management of a Pregnant ALK-Positive Lung Cancer Patient With Alectinib-Induced Pneumonitis and Bilateral Globus Pallidus Necrosis Postpartum.
     Clin Lung Cancer. 2023 Aug 30:S1525-7304(23)00181.
     PubMed    
     
     
     
299. BRAMBILLA M, Beninato T, Piemontese A, Mazzeo L, et al
     Exploring the Role of Immunotherapy-Based Treatments for Advanced Non-Small-Cell Lung Cancer With Novel Driver Alterations.
     Clin Lung Cancer. 2023 Aug 23:S1525-7304(23)00149.
     PubMed     Abstract available
     
     
     
300. EBADI M, Ladbury C, Liu J, Rock A, et al
     Stereotactic Body Radiation Therapy for Oligoprogressive and Oligorecurrent Non-Small-Cell Lung Cancer.
     Clin Lung Cancer. 2023 Aug 22:S1525-7304(23)00180.
     PubMed     Abstract available
     
     
     
301. PETRANOVIC M, McDermott S, Mercaldo S, Little BP, et al
     Impact of Baseline Interstitial Lung Abnormalities on Pneumonitis Risk in Patients Receiving Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer.
     Clin Lung Cancer. 2023 Aug 21:S1525-7304(23)00179.
     PubMed     Abstract available
     
     
     
302. HONG YR, Wheeler M, Wang R, Karanth S, et al
     Patient-Provider Discussion About Lung Cancer Screening by Race and Ethnicity: Implications for Equitable Uptake of Lung Cancer Screening.
     Clin Lung Cancer. 2023 Aug 18:S1525-7304(23)00175.
     PubMed     Abstract available
     
     
     
303. HASHIMOTO K, Murakami Y, Omura K, Takahashi H, et al
     Prediction of Tumor PD-L1 Expression in Resectable Non-Small Cell Lung Cancer by Machine Learning Models Based on Clinical and Radiological Features: Performance Comparison With Preoperative Biopsy.
     Clin Lung Cancer. 2023 Aug 11:S1525-7304(23)00155.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.